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DEVELOPMENT OF BIOANALYTICAL METHODS FOR CLINICAL
APPLICATIONS AND DRUG SCREENING

XIAOHAN CAI

ABSTRACT

In the past decade, bioanalytical method development has become an integral part of
clinical diagnosis, biomarker discovery, and drug discovery and development. The new
and emerged bioanalytical technologies allow the quantitative and qualitative analysis of
small molecules and biomolecules with high sensitivity and specificity. Specifically, the
bioanalytical methods based on LC-MS and methylation-specific PCR are well suited for
detecting low-abundance metabolites, proteins, and DNA in biofluids and tissues for
biomarker investigation. They offer great clinical promises for early diseases diagnosis
and therapeutic interventions. Besides, the LC-MS/MS quantitative method is essential
for the estimation of pharmacokinetic and toxicological properties in drug screening.

In this work, modern bioanalytical technologies, together with their applications from
biomarker discovery and validation in metabonomics, genomics and proteomics to drug
discovery, were reviewed. Dependent on the type of molecules analyzed, different
methods were established to achieve accurate and reliable detection. LC-MS/(MS)
methods were developed and validated for quantitative analysis of bile acids and anticancer agent JCC76. The former has been successfully applied in a clinical study for the

v

diagnosis of inflammatory bowel diseases; and the latter has been utilized in a
pharmacokinetics study for drug screening and optimization. In terms of proteomics
profiling, a LC-MS/MS method was demonstrated for comparative analysis of serum
peptides with the successful identification of a potential biomarker for ovarian cancer.
Lastly, a comprehensive DNA methylation profiling for hepatocellular carcinoma was
conducted through methylation-specific PCR methods. These methods enabled sensitive
and specific detection of DNA hypermethylation on several tumor-associated genes.

In addition, this work discussed a major challenge of matrix effect in quantitative method
development. Possible solutions were proposed for matrix effect prevention and
troubleshooting. Moreover, standard addition coupled with internal standard method and
optimizing sample extraction method was illustrated for compensating or minimizing
matrix effect in chapter II and chapter III, respectively.
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CHAPTER I

INTRODUCTION OF BIOANALYTICAL METHODS FOR CLINICAL
APPLICATIONS AND DRUG SCREENING

1.1. General introduction of bioanalytical methods and their applications

Bioanalytical science, with a focus on qualitative and quantitative measurements in
biological materials, plays a key role in understanding diseases, clinical diagnosis, and
drug discovery and development. The technologies in biomedical science have made
significant progress over recent years. This facilitates bioanalytical method development
to

become

an

integral

metabolism/pharmacokinetic

component

(DMPK),

and

of

biomarker

toxicological

discovery,

monitoring.

drug

Advanced

technologies and enhancements of conventional platforms emerged from bioanalysis
fulfill the requirements of clinical and pharmaceutical fields, including the improvement

1

in mass spectrometry detection, fast chromatographic separation, high-throughput sample
pretreatment, and melting curve analysis with high resolution for genomic assays.

Early diagnosis of diseases has great significance in improving survival rates and
minimizing current invasive diagnostic procedures. This leads to another major clinical
need in the accurate detection of molecular biomarkers for chronic illnesses and cancers.
The biomarker study monitors different biological entities including nucleic acids,
proteins, and metabolites to reflect the pathophysiology and progression of diseases. Ideal
biomarkers need to be well-understood for their functions in the pathogenic processes and
their values for clinical diagnostic, prognostic, and predictive outcomes. However, these
molecular biomarkers often present in low abundance in the biological samples, bringing
great challenges in reliable detection and validation. Although these challenges remain,
there is a large number of biomarkers developed currently and to be assessed in clinical
studies for their diagnostic and prognostic applications [1].

Besides the broad bioanalytical applications in biomarker discovery, the impressive
growth of quantitative bioanalysis has been also well-documented in pharmaceutical drug
discovery and development. In the past decade, more than 500 novel drugs were
approved by U.S. Food and Drug Administration (FDA) to prevent and treat human
diseases [2]. Each year, more than 3000 on-going clinical trials are carried out in the drug
development phase [3]. Despite the enormous amount of lead compounds screened in the
drug discovery phase, the drug development process is costly and risky with very low
rate of clinical success. This drives the rational lead optimization in the earliest stage of
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drug discovery to improve the likelihood of drug approval and to prevent drug
withdrawal on the market. Quantitative bioanalysis serves as a major tool for
understanding pharmacological properties including absorption, distribution, metabolism,
and elimination (ADME), as well as toxicity to guide the drug screening for lead
candidates.

1.1.1. Clinical applications for biomarker studies

Biomarkers are defined as indicators of normal biological processes, pathogenic
processes, or pharmacological responses to a therapeutic intervention according to the
National Institutes of Health (NIH) working group [4]. Cancers are the most studied
diseases for biomarker discovery since the early detection of cancers before metastasis is
always desirable to greatly improve survival. With advanced technologies for molecular
biomarker measurement, thousands of potential biomarker candidates have been
discovered and linked with cancers. These disease-related molecules may involve in cell
regulatory and post-translational modification processes as proteins, alter the expression
of downstream target molecules as nucleic acids, and represent metabolic responses as
endogenous small molecules.

Among different biomarker discovery tools, proteomics allows the identification,
characterization, and quantification of differential protein expression involved in normal
and pathological states. Blood is the most commonly used sampling source for proteome
profiling since blood sampling is non-invasive compared to tissue biopsy. In cancers, the
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intra- and inter-cellular events happen at the tumor tissue microenvironment, introducing
the changes of accumulative protein expression in the circulating blood stream. The
differentiated proteomic pattern may reflect the development of malignancy and can also
provide diagnostic, prognostic and predictive value for cancers. Extra-cellular nucleic
acids in biofluids is another popular source of biomarker investigation, since it can reflect
the cancer cell transformation induced by gene mutation or hypermethylation [5]. The
circulating free DNA and cancer-specific RNA have been profiled in numerous genomic
biomarker studies for the diagnosis and staging of cancer diseases.

The epigenetic changes in DNA methylation are also commonly associated with
tumorigenesis. Taking place in the promoter region of CpG islands, the methylation of
cytosine residue in normal cells is well-maintained in a homeostasis through a feedback
regulation of DNA methyltransferase mechanism [6].

The disturbances to normal

cytosine methylation are fundamental contributors to the malignancy of cancer [7]: the
hypermethylation of tumor suppressor genes results in the inactivation of gene
transcription and thus the loss of their intrinsic functions; global change of
hypomethylation in a wide area causes repeated sequences and transposable elements,
ultimately resulting in the loss of genomic stability and increased mutations [8]. These
aberration events are the rationales for discovering potential genomic biomarkers to aid
the diagnosis, predict the clinical outcomes, and subsequently guide the therapeutic
treatment. Therefore, it is of crucial importance to develop bioanalytical tools that
support the profiling of aberrant methylation.

4

Besides the large biomolecules in cancer biomarker study, the endogenous metabolites in
cells, tissues, and body fluids start to gain more interest for reflecting human health status
from their quantitative information. The most common example in clinical application is
the measurement of cholesterol to monitor the cardiovascular disease by physicians. The
metabolic signatures of patients reflect the biochemical changes in diseases and the
disturbed metabolic pathways. The analysis of glycerophospholipids, fatty acids, steroid
metabolites, and bile salts have been conducted for examining abnormal lipid metabolism
and interaction of intestinal microflora for liver and intestinal diseases. These research
areas provide useful sources for metabolic biomarker profiling.

1.1.2. Bioanalysis applications in drug discovery and development

Drug PK and toxicity properties are key parameters in the screening and optimization of
lead compounds in the drug discovery phase. An ideal drug candidate should demonstrate
the ability be absorbed in the blood stream, reach desirable concentration for effective
activity, and be eliminated without producing toxic metabolites.

High-throughput PK screening usually starts from in-vitro assays to study the drug-drug
interaction and metabolism using liver microsomes and hepatocytes as experimental
systems. However, the in-vitro results cannot truly represent the real physiological
environment and may lead to mistaken conclusion about drug metabolism. Therefore, it is
essential to assess the PK parameters in vivo to improve the candidate selection through
animal models.

5

In order to accurately define the drug behaviors in vitro and in vivo, bioanalytical support
has been a prerequisite in the pharmaceutical industry. The large amount of compounds
involved in the lead optimization requires the quantitative method to be accurate,
sensitive, and high-throughput to facilitate drug discovery. These requirements can be
fulfilled by accurate sampling procedures, advanced chromatographic and mass
spectrometric techniques, as well as automated sample preparation methods.

1.2. Modern bioanalytical technologies

Modern bioanalytical technologies have been significantly broadened in the last decade,
demonstrating its ability in accurate qualitative and quantitative determination for
protein, nucleic acids, small molecular metabolites, and drugs in biological materials. The
major methodologies used for proteomics investigation are based on mass spectrometry
(MS). The dramatic progresses of MS instrumentation refine mass accuracy, resolution,
and dynamic ranges, ensuring the successful detection of low abundance proteins in
biofluids and structural confirmation with their characteristic precursor and fragment
ions. In addition, the robust and reliable liquid chromatography (LC) system in low flow
rate has greatly improved the sensitivity for the MS detection and confidence for
structure illustration.

Besides its application in protein analysis, the hyphenation of LC and MS (LC-MS) is
established as the state-of-the-art methodology for the quantitation of small molecular
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compounds due to its specificity and sensitivity. It is now widely accepted as the
preferred method for the quantitative measurement of small molecule drugs and
endogenous metabolites in various biological matrices including plasma, serum, blood,
urine, intestinal fluid, and tissue.

With respect to epigenetic biomarker discovery, the majority of DNA methylation assays
are based on bisulfite reaction, methylation-specific PCR (MSP), and melting curve
analysis. Sodium bisulfite converts cytosine to uracil at unmethylated CpG site, leaving
methylated one unchanged. The MSP methods with designed primers selectively amplify
methylated DNA, bringing high analytical specificity and sensitivity.

1.2.1.

Principles of LC-MS

1.2.1.1. LC separation

LC is the basic separation platform for bioanalysis. With this technique, target analyte
can be separated with interfering protein, salts, and phospholipids content in complicated
biological materials. The separation mechanisms of liquid chromatography are based on
the distribution of analyte between the liquid mobile phase and a stationary phase.
Depending on different type of stationary phases, different distribution mechanisms are
applied.

7

Adsorption mechanism is applied for both normal-phase (NP) chromatography and
reverse-phase (RP) chromatography. In NP chromatography, the stationary phase is a
polar silica gel and the mobile phase is a non-polar solvent such as hexane, pentane, and
chloroform. NP chromatography is preferable for non-polar analyte and the retention
decreases as the non-polarity of analyte increases. Opposite to NP chromatography, the
stationary phase of RP chromatography uses non-polar silica based packing materials
after the surface modification with C8, C18, or phenyl. Accordingly, the retention
decreases with increasing polarity of the compound and the amount of polar solvents. RP
chromatography is suitable ideally for polar and ionic compounds, which makes it the
most widely used LC application. The interaction of analyte with stationary phase and
mobile phase solvent greatly depends on the hydrophobicity of the analyte.

Ion-exchange chromatography is based on the ion exchange equilibrium between the
ionic or polar compounds with the stationary phase. With opposite charge with the ionic
functional group of the stationary phase, the ionic compounds can be retained. The
elution speed is related with the ionic strength of the counter-ions, pH environment, and
the modifier contained in the mobile phase.

Size-exclusion chromatography is usually applied in the separation of macromolecules
according to their ability to penetrate into the pores of stationary material. The elution
time of analyte is merely based on their size, but not molecular weight. The retention
decreases as the size increases.
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Besides the aforementioned traditional chromatography, there are some modern
approaches for improving chromatographic resolution and separation efficiency: ultraperformance liquid

chromatography (UPLC), monolithic chromatography, and

hydrophilic interaction chromatography (HILIC). Underlying the same basic principle
with RP-LC, UPLC utilizes column with sub-2 μm particle size and a system that can
handle elevated pressure. UPLC has great advantages in resolution, sensitivity, and speed
over conventional HPLC, and thus is considered as a better tool for high throughput
analysis. Monolith column is packed with highly porous material, which is designed to
handle fast flow rate and ensure sufficient surface for separation at the mean time.
Consequently, the separation speed and sample throughput are significantly increased.
HILIC is a valuable alternative to NP chromatography for very polar compounds because
polar compounds are hardly retained and experience bad reproducibility when using NP
chromatography. In addition, the large portion of organic mobile phase used for the
HILIC elution increases the sensitivity when coupling MS with LC for detection.

In general, a sample is separated and analyzed by LC in the following sequence: the
sample solution is injected through an injection port, and then delivered by the mobile
phase by high-pressure pumps, and finally flowed into the column for retaining and
further elution (Fig. 1.1). The instrumentation design should consider the following issues:
the high-pressure is generated when the solvents are pumped into the small particle filled
stationary phase; the dead volume of connecting tubes, the injector, and the mixing valve
should be minimized to prevent the reduction of analyte peak resolution; the sample
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residue on the tubing and injector should be avoided for carry-over issue in quantitative
analysis.

10

Figure 1.1, The instrumentation setup for LC separation

11

In this work, all small molecule compounds and peptides were separated by RP-LC with
a C18 column and mass spectrometric detection. A guard column was used to prevent
potential damages from the injected crude samples and proteins from the biological
matrices. As the heart of LC system, the column needs to achieve adequate separation
with a short time, maintain the precision for the retention, and have good stability in a
broad pH range.

1.2.1.2. MS detection

MS has become a crucial part for pharmaceutical analysis and biomolecules research
because of the improvements in ionization methods in the past decade. Taking
advantages of powerful separation and sensitive detection, LC-MS analysis is well-suited
for structural elucidation, accurate quantification, and metabolites prediction in complex
biological matrices. The analyte in liquid flow eluted from the LC goes into three
modules of ionization source, mass analyzer, and detector, undergoing ionization and
evaporation, separation, and detection, respectively.

As the basic interfacing strategy, atmospheric-pressure ionization (API) enables the MS
analysis by generating ions in a steam of liquid after LC separation. A number of API
sources such as electrospray (ESI) and atmospheric-pressure chemical ionization (APCI)
were developed to transfer the analyte from the liquid phase to the gas phase in MS with
different ionization mechanisms.
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In the ESI source, a highly positive or negative voltage is applied to the end of a steel
capillary probe, where the sample solution is introduced (Fig. 1.2). When traveling along
the capillary probe, the sample liquid is sprayed with excess charge. The nebulization
process helps the formation of small droplets for ions in solvent vapor. During their flight
from the electrical field to the MS proper, the droplets pass through an evaporation
chamber, allowing the evaporation of solvents with the help of heating gas and
nebulization gas. In the mean time, the quick evaporation process condenses the droplets
and increases the surface charge density. At the end of the evaporation, the light solvent
molecules diffuse away, leaving ions to enter into the MS analyzer.
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Figure 1.2, The schematic diagram of ESI source
(http://www.ucl.ac.uk/ich/services/lab-services/mass_spectrometry/metabolomics/hplc)
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Unlike ESI, the ionization process of another liquid-based ionization source APCI occurs
in gas phase. Without applying high voltage, the APCI capillary enables the volatile
liquid sample to be heated and spayed first, and then a corona discharge needle with a
high voltage generates ions from the aerosol cloud through interaction of reagent gas and
electrons.

When ions are accelerated by the applied electric or magnetic field, the mass analyzer
separates the ions according to their mass to charge ratio (m/z). Typical mass analyzers
include quadrupole MS, ion-trap MS, and time-of-flight (TOF) MS with their own
characteristics and applications.

The quadrupole instrument selects ions with a certain m/z to pass through the four
parallel rods with certain direct-current potential and radiofrequency. Triple quadrupole
MS allows the filtration of incoming ions by the first quadrupole, the fragmentation of
selected ions by the second quadrupole, and the filtration of selected fragments by the
third quadrupole, achieving high specificity. Similar to quadrupole MS, the ion-trap MS
captures ions by a three dimensional manner in the electrical and magnetic combined
fields (Fig. 1.3). The ion-trap MS takes advantages of its high sensitivity and resolution.
The TOF MS accelerates ions and determines the flight time needed for ions moving
from the ion source to the detector. TOF MS is characterized with advantages in high ion
transmission and unlimited mass range, but with disadvantages in precursor ion
selectivity. The modern MS instrument hybridizes different type of MS analyzers on one
instrument, facilitating broader MS/MS applications.

15

Figure 1.3, The operation of quadrupole MS and ion-trap MS
(www.currentseparations.com/issues/16-3/cs16-3c.pdf)
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1.2.2.

Quantitative LC-MS(/MS) analysis for small molecules

The most prevalent method for small molecules quantification is based on quadrupole
MS with ESI or APCI interface since 1990’s. The detection of target analyte ions utilizes
selective-ion-monitoring (SIM) and multiple-reaction-monitoring (MRM) approaches for
LC-MS and LC-MS/MS methods, respectively.

The SIM mode detection is operated on single quadrupole instrument, with a particular
m/z value selected for the target analyte ion. Because the impurities including proteins,
phospholipids, and salts in the sample matrices may have the same m/z with target
analyte, the LC-MS analysis requires more elaborate sample extraction and LC separation.
Compared with SIM, MRM detection is more specific and sensitive since triplequadrupole (QqQ) MS analyzer is applied for ion filtration and collision. Particular
precursor ion and product ion are selected for detection based on their unique
fragmentation pathway, resulting in a great improvement of signal to noise ratio (S/N)
comparing to that of SIM.

The quantitative LC-MS(/MS) method development generally follows the workflow in
Fig. 1.4. A successful bioanalytical method requires three interlinked methodologies in
MS detection, chromatographic separation, and sample preparation. Some important
aspects and challenges such as mobile phase choice, sample pretreatment, and matrix
effect are discussed in the following sections.
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Figure 1.4, Method development workflow for small molecule bioanalysis
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1.2.2.1. Mobile phase optimization

Mobile phase additives are often added in RP-LC for reproducible retention and the
improvement of resolution and sensitivity when using MS as a detector. However, only
volatile additives are compatible with LC-MS, because the non-volatile buffers such as
phosphates may clog the ionization source and cause signal suppression.

In addition,

some volatile additives help the retention but deteriorate the MS ionization. For example,
trifluoroacetic acid (TFA) is commonly used as an ion-pairing agent for increasing the
retention of polar compounds. Nevertheless, it is also reported to induce significant signal
suppression for some negatively and positively charged compounds [9-11].

Besides the LC modifiers, the pH of the mobile phase also has a large impact on both
retention and ionization. By adding volatile acids such as formic acid, acetic acids, and
their salts with ammonium in the mobile phase, the protonation of basic molecules under
positive ionization mode is favored in acidic condition. Similarly, the deprotonation of
some acidic molecules in negative-ion mode can increase the response by adding
ammonium hydroxide as mobile phase additive. But these conditions may cause an
adverse effect for retention if the hydrophobic interaction between analyte ions with the
stationary phase is not sufficient [12]. In addition, the concentration of the additives is
also critical since the MS response may be reduced under very high concentration, but
concentration that is too low may lack buffer capacity. To solve the dilemma between
retention and ionization, the selection of mobile phase composition needs to carefully
consider all the characteristics of individual analyte.
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1.2.2.2. Sample preparation

Although LC is a powerful tool for separation, the sample pretreatment for biological
sample before injecting to LC-MS is essential for accurate and reproducible analysis. The
biological sample matrices are very complicated with much higher content of proteins,
salts, and endogenous lipids than target analyte. The large protein content in plasma
sample is problematic due to its clogging of column and reducing analytical efficiency.
Also, the endogenous interference and salts in most biological samples may suppress the
ionization of analyte.

Conventionally, the sample cleanup has been performed by protein precipitation (PPT),
liquid-liquid extraction (LLE), and solid phase extraction (SPE). PPT is popular when
handling plasma sample because it is simple and fast. But the major disadvantage for PPT
is that residues consisted of salts and endogenous material after the removal of proteins,
which may greatly affect the MS detection [13]. Besides the use of organic solvents for
denaturing proteins, other PPT additives such as acids, metal ions, and salts were reported
to improve the efficiency of protein removal and disrupt the protein-drug binding [14].

LLE is an efficient technique to separate analyte from sample matrices based on the
different distribution in the water-immiscible organic phase and aqueous phase. It is
successful in giving excellent sample cleanup. But the disadvantages for LLE include the
relatively large sample and solvent consumption, possible formation of emulsion, and
unsuitability for hydrophilic compounds. Based on the conventional LLE, the salting-
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out-assisted-LLE is developed as a more convenient alternative by adding concentrated
ammonium salt solution into a mixture of biological sample and water-miscible solvents.
In this way, high-throughput LLE can be applied through the automation of the handling
process in 96-well plate.

The separation process of SPE method prior to sample analysis is similar to LC
separation. The analyte is isolated relying on its affinity difference with the liquid sample
solution and the solid SPE sorbents. Depending on the interaction of analyte and the
selected solid phase, the SPE sorbents vary from polymer based ion-exchange materials
to silica based materials. Typical SPE procedures start with the conditioning of the
cartridge by a solvent or water (Fig. 1.5). Then the sample is added onto the cartridge and
the analyte interacting with the sorbent is retained. While the interferences are removed
after rinsing the cartridge with buffer or solvent, the analyte can be eluted with an organic
solvent and further concentrated by evaporation and re-constitution.
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Figure 1.5, Illustration of four steps when performing SPE
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Conventional SPE is performed on single cartridge, with the limitation for large volume
of eluates and subsequent time-consuming evaporation process. The on-line SPE mode
can be fully automated for directing injection of sample without any pretreatment. This
advantage promotes the use of on-line SPE and 96-well plate, together with a columnswitching system in high-throughput analysis to facilitate the extraction speed. The
runtime for high-throughput analysis using SPE-LC-MS was reported to be within 5 min
for many applications [15-17].

1.2.2.3. Matrix effect

Matrix effect is one of the major issues encountered during LC-MS method development
and validation [18]. The phenomenon of matrix effect is observed when the ionization of
analyte is suppressed or enhanced by the undetected co-eluting components from the
biological matrix. The adverse results of matrix effect are reduced sensitivity for the
detection and deteriorated precision and accuracy of the assay. According to the FDA
guideline, it is required to assess the matrix effect when developing a reliable
bioanalytical method.

In order to quantitatively determine the absolute matrix effect, an useful strategy was
proposed by Matuszewski et al. [19]. The matrix effect is evaluated by comparing the
signal response of analyte obtained from a neat solution with that from a post-extraction
solution. In this way, two sets of samples are examined: one set is prepared by spiking
standard analyte in neat solution and the other set is prepared by spiking standard analyte
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at the same concentration in the extracted solution of blank biological sample, which is
termed as post-extraction solution. The difference of response from these two sets
determines whether signal is suppressed or enhanced. More importantly, the relative
matrix effect should be evaluated by comparing the response of analyte in post-extraction
solution from different blank matrix sources.

The post-column infusion of analyte is usually helpful to locate the co-eluting substances
causing suppression in an LC run. A mixing tee is setup after the column elution and
prior to MS ionization interface (Fig. 1.6). The post-extraction solution of a blank
biological matrix is injected into the LC system, and then eluted by the mobile phase
from the column. At the mixing tee, the matrix eluents mix with the analyte, which is
infused constantly through an individual syringe pump. The MS monitors the signal
change after the injection of post-extraction solution. The signal response of analyte
should be expected to be steady in the absence of suppressing impurities. When the ion
suppression or enhancement of analyte is present, the signal response will drop or
increase at certain time points when interferences are eluted out, which can be easily
observed on the chromatogram. In this way, the elution time of the ionization
interferences and the extent of suppression or enhancement effect can be assessed
through several continuous runs. The subsequent experimental design of analyte elution
should avoid the co-elution with interferences.
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Figure 1.6, The post-column infusion experiment used for the assessment of matrix
effect
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Matrix suppression is induced by different reasons ranged from endogenous compounds
from inadequate sample clean-up, ion-suppression mobile phase additives, choice of
ionization method, to sample storage conditions. One of the most extensively used and
efficient method to solve matrix effect issue is the utility of stable isotope labeled (SIL)
internal standard. Since the SIL internal standard has very similar chemical structure and
properties compared to the analyte, the ionization suppression or enhancement effect on
both compounds is expected to be the same level. However, the SIL internal standard is
costly and sometime hard to obtain. It is also problematic for tackling the “cross talk”
problem if the purity of SIL internal standard is not adequate.

The matrix effect can also be minimized by improving the sample extraction method to
remove the interferences. The endogenous compounds in biological samples have
different polarity and thus are difficult to be completely removed by sample extraction
methods. However, choosing the optimal sample preparation to reduce the amount of
interferences is an efficient approach to ensure success in method development. Little et
al. identified the phospholipids as a major contributor of matrix effect in blood and
plasma by MS/MS using different extraction methods [20]. Their results suggested that
the glycerophosphocholines caused matrix effect in both positive and negative
ionization, with larger effect for isocratic elution than gradient elution. As the effect of
different sample pretreatment methods on matrix effect, it is reported that LLE had
lower signal suppression compared to SPE, followed by the PPT extract, which usually
contains the most endogenous residues (Fig. 1.7) [21].
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Figure 1.7, Infusion chromatograms (2.5 min) showing the ability of different
sample preparation methods to remove endogenous sample components [21]. Panels
(a) through (f) show the SRM XIC of a post-column infusion of phenacetin showing
the effect of an on-column injection of 10 mL of a blank plasma sample prepared by
each of the tested sample preparation methods. (a) Plasma protein precipitation
blank. (b) Plasma Oasis SPE blank. (c) Plasma MTBE liquid-liquid extraction blank.
(d) Plasma Empore C2 disk SPE blank. (e) Plasma Empore C8 disk SPE blank. (f)
Plasma Empore C18 disk SPE blank.
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Alternatively, adjusting the chromatographic conditions is another approach to reduce or
eliminate the matrix suppression. In the RP-LC separation, the suppression effect is often
found in an early time of isocratic elution program and at the end of gradient elution
during the post-column infusion. Therefore, it is wise to alter the elution of target analyte
at other regions of the chromatogram where the matrix effect is the lowest. Some mobile
phase additives such as triethylamine (TEA) and TFA can also induce matrix effect in
LC-MS analysis. The strong ion-pairing ability of these additives helps trap very polar
compounds in the column and reduce peak tailing, but it also masks the detection by
neutralizing the positive charge of analyte. The use of ammonium salts as a substitution
or the choice of other columns with different retention mechanism can relieve this
problem.

In bioanalytical method development, matrix effect is more frequently reported in ESI
interface MS than APCI since the ionization mechanisms are different in these two
sources. In ESI, the analyte is charged when traveling in the electrical probe, then
nebulized to small droplets, and at last evaporated in the gas phase. When the interfering
compounds compete with the analyte for the surface charge, the charge transfer occurs if
the interferences have higher proton affinity, causing the lost of charge for the analyte
and the decrease of MS intensity. Compared to ESI, the APCI of analyte in liquid
undergoes opposite sequence for evaporation and ionization. The evaporation of liquid
solvent takes place in the capillary before the ionization by charge transfer from the
corona probe.
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In addition to the endogenous compounds causing matrix effect problems, other often
neglected sources from the dosing vehicles and blood anticoagulant can also result in ion
suppression. Dosing vehicles including propylene glycol, Tween 80, and hydroxypropylβ-cyclodextrin are often used in the pre-clinical PK studies. Undetected matrix effect in
the post-dose samples would give underestimated drug concentration and generate PK
results with large errors. It also has been suggested that heparin should be avoided for
separating plasma from blood during sample handling [22]. Sodium EDTA usually is
preferred for anticoagulation in the PK and toxicokinetics studies for the prevention of
matrix effect.

1.2.3.

Mass spectrometric analysis for proteins

In the scientific process of biomarker discovery and evaluation, a lot of assays including
ELISA, functional assays, flow cytometry, immunohistochemistry, and MS have been
developed for biomarker analysis [23]. The interfacing of LC with MS, with the ability in
qualification and quantitation, is the principal technique to define proteomes. Direct
sequencing can be obtained by generating protein or peptide signature spectra and then
imputing the spectra fingerprint into proteomics database.

1.2.3.1. Identification of differentially expressed protein candidates

Body fluids are the major sources to characterize proteome. However, the analysis of
proteins in human blood or urine presents a lot of challenges owing to the dynamic range
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of protein concentration and complexity of sample components. The pre-fractionation of
proteins is necessary to deplete the high-abundance proteins before MS analysis. With
this purpose, different separation methods have been well developed prior to protein
characterization.

Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) tandem with MS
analysis is the first tool used to separate and identify differentiated proteins [24]. 2DPAGE separates thousands of proteins by two steps. Firstly, samples are isolated by their
different isoelectric points and by their molecular sizes. In this step, the protein pattern
can be visualized by staining the gel. Secondly, the spots representing differentially
expressed proteins are excised and digested into peptides by enzymes prior to MS
analysis. However, when both abundant and less abundant proteins are presented on the
same gel, it is necessary to determine the relative intensity of protein spots. Matrixassisted desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) is
commonly applied in spot identification to generate protein or peptide fingerprint. The
MALDI-TOF MS analysis takes advantages in unlimited mass range and fast analysis
speed. Bioinformatics can subsequently be utilized to search the proteomic database to
identity the targeted proteins or directly analyze the results for discriminating protein
patterns from control to patient samples.

Although 2D-PAGE with MALDI-TOF MS analysis is a simple and widespread tool for
the analysis of complex protein mixtures, it have several limitations such as the relative
low resolution of 2D-PAGE separation and the reproducibility of detection, and it is
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restricted to protein less than 20k Da [25]. Micro-scale or nano-scale chromatographic
separation enhances the speed and efficiency comparing to conventional 2D-PAGE,
facilitating the incorporation of high resolution LC in tandem MS as the primary protein
identification platform.

The LC-MS/MS protein analysis can be performed on various mass spectrometers, such
as quadurpole and linear ion traps, Orbitrap, and quadrupole-TOF. The bottom-up
method for protein primary sequence determination involves the enzymatic digestion of
protein into small peptides (Fig. 1.8). Retaining the digested peptide in acidic condition,
the C18 reverse-phase microcapillary or nano-LC columns are the most commonly used
ones to fractionate peptides with high resolution.
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Digested Peptide

LC column

Complex protein mixture

Figure 1.8, Bottom-up proteomics analysis using LC-MS/MS. Trypsin digestion is the
first step for the analysis of a complex protein mixture. Afterward, the sample
containing tryptic peptide is injected into the HPLC column of the LC-MS/MS system.
The mass spectrometer generates parent (MS1) spectrum and fragmentation (MS2)
spectrum created by CID. The computer will use the MS2 spectrum together with MS1
spectrum to compare the database containing theoretical peptide spectra to identify the
protein of origin.
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The gradient program of the LC system helps the elution of the peptides. When delivered
to the mass spectrometer in acidic environment, the peptides are converted into cationic
form with single or multiple charges [26]. The first stage is to produce MS1 spectra for
the m/z of various peptides. To generate more information for peptide identification, the
fragments of selected peptide ions (precursor ions) are initiated. To produce fragment
ions, tandem mass spectrometric analysis (MS/MS) uses collision-induced dissociation
(CID) to generate MS2 data for peptide sequence information. By searching the protein
database with the acquired MS/MS spectra, the software program can identify protein
with matching peptide mass fingerprinting. Clearly, the higher mass accuracy obtained
from precursor ions and product ions, the more confidence for protein identification.

1.2.3.2. Quantitative protein analysis

With the speed-up of generating biomarkers, the center of proteomics has shifted from
biomarker discovery to biomarker evaluation and quantification. It is necessary to
compare the amount of differentially expressed proteins among healthy and disease status.
Therefore, the development of accurate methods to quantify biomarkers of interest is a
reliable theme for biomarker evaluation. Currently, the established techniques for protein
and peptides quantification include two general strategies: 1) non-labeling methods by
correlating MS signal with relative protein quantity and 2) the use of stable isotope
incorporation prior to MS analysis.
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In non-labeling quantification, the quantitative information for specific peptide is
derived from according ion intensity or peak areas in complex peptides mixture. The
accurate quantification needs a careful calibration of instrument system and
normalization of MS spectra. For LC-MS/MS quantification, peptide ion intensity
counting of MS mode and spectral counting in MS/MS mode are extensively used for
ion detection. With respect to peptide ion counting, the number and intensity of
precursor ion or peak area at selected m/z can be obtained. The spectral counting
approach refers to the number of fragment ions generated from selected peptide. The
peptide levels are yielded by comparing referring the abundance of peptide between
samples in two or more separate LC-MS/MS runs. Label-free approach for quantitative
proteomics is preferable due to its low cost and no limitation for sample numbers [27].

However, there are still controversies for the reliability of label-free quantitative
analysis. The accurate quantification of this approach requires the minimization for
variations between different runs, high resolution for the chromatography to finding
correlated peptide, and high MS accuracy to prevent interfering signals with similar m/z.
It also assumes that the linearity of response is the same for every peptide, but in fact
the spectrum count response varies from different peptides. Because of the dynamic
range of peptides in a sample, the existence of high abundance peptide in the complex
mixture will affect the accuracy of low abundance peptide quantization.

The major stable isotope labeling methods include using isotope coded affinity tags
(ICAT) and isobaric tags for relative and absolute quantification (iTRAQ) [28]. The
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basic principle of ICAT relies on a special affinity tag to react with cysteine residues
and allows differentially labeled samples to be resolved with MS analysis. Two
different tags, which are identical except for one has hydrogen and the other one has
deuterium atoms in the linker, react with samples before protein digestion [28]. Their
mass difference allows the relative quantitative measurement by MS. The
disadvantages of ICAT are its limitation for proteins containing cysteine residues only
and high cost due to the isotope reagent.

The iTRAQ approach allows multiplexed quantification by targeting all free amines at
N terminus of all peptides and the epsilon-amino group of lysine residues. This
technique enables the analysis of up to 8 samples in one run. The iTRAQ tags contain
reporter group with mass from 114 to 117 Da, balance group from 28 to 31Da, and a
protein-reactive group. During each MS scan, each labeled peptide displays the same
mass to charge ratio. However, the dissociation of the reporter groups displays different
m/z after the fragmentation under MS/MS mode. Signals from peptides after isobaric
labeling are acquired for both MS and MS/MS scanning mode, thus improving the
sensitivity and specificity of detection [29]. This property has great potential in the
quantification of low abundance proteins. iTRAQ coupled with LC-MS/MS has been
used as in the serum biomarker in several studies and it shows promise in determining
differential expression profiles for cancer diagnosis, prognosis or monitoring of
treatment [30].
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When the quantitative information is derived for cataloging the protein files in a sample,
the biomarker development requires careful follow-up validation, which includes the
application of targeted proteomics methods. Targeted proteomics focused on individual
proteins or a panel of proteins. When the use of isotope labeled methods only can provide
relative quantitative information, the use of a standardized reference in the sample
provides the absolute quantification information (AQUA). It is performed by spiking an
isotopically-labeled internal standard into a biological sample prior to MS analysis. The
ratio of labeled to unlabeled peptide determined by MS analysis can be calculated and the
abundance of specific protein can be derived. Combining AQUA with MRM method in
MS analysis, the specificity and accuracy can be improved for absolute quantification.
MRM involves the selection of parent ions and then monitoring the fragmentation ions
from the selected parent ions, thus enabling this technique highly specific and sensitive.
Because the MRM detection limit allows at low as ng/ml level, this method offers the
most promise for biomarker validation.

To develop proteomics biomarkers with high specificity and sensitivity for clinical
application, several phases including biomarker discovery, evaluation, determination of
biological relevance, and development of clinical assay are need to follow. Huge
challenges were presented such the complexity, variation and dynamic range of proteins
in biological samples. The new MS technologies play the most critical role in the
improvement of resolution and sensitivity, bringing promises for more clinical successes.
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1.2.4. PCR based methods for methylation profiling

DNA methylation is the most studied epigenetic changes related to normal biological
processes and many diseases, especially in cancer development. This covalent
modification of cytosine mostly happens at CpG dinucleotides rich sites, which are
associated with gene promoters. While the methylation in normal cells is regulated by the
DNA methyltransferases in a steady status for a stable genome, the aberrant gene
methylation represses the transcription of downstream genes. In the process of
tumorigenesis, a large number of tumor suppressor genes were found to be
hypermethylated in the promoter regions [31]. Based on these findings, the investigation
on DNA methylation has become one of the most popular areas in molecular oncology.
Technologies for the genomic DNA methylation profiling are designed with enormous
improvements with regarding to sensitivity, the elimination false-positive results, and
sample throughput.

In currently used methodologies for methylation profiling, bisulfite conversion based
method is the fundamental one to investigate the gene-specific methylation. With
standard sequencing method, the similar base-pairing sequence of methylated and
unmethylated cytosine cannot be distinguished. Sodium bisulfite treatment with genomic
DNA can solve this problem by chemical reaction. Under certain conditions, sodium
bisulfite specifically deaminates unmethylated cytosine to uracil but leaves the
methylated cytosine unchanged (Fig. 1.9.). The uracil is replaced with thymine in the
followed PCR amplification after bisulfite conversion. After this reaction, standard

37

methods such as sequencing, pyrosequencing, PCR, or mass spectrometry can be used to
analyze the bisulfite-converted DNA product [32-34].
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Figure 1.9, Strategy to distinguish unmethylated cytosine and methylated
cytosine by bisulfite reaction
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However, bisulfite treatment may give inaccurate results when the incomplete conversion
of unmethylated cytosine is misinterpreted as methylated cytosine. It is critical to ensure
the reaction is complete for unmethylated DNA by spiking known unmethylated DNA
with the reaction as control. Another issue is the partial degradation as a result of DNA
depurinization at acidic pH, which limits the sensitivity of the PCR reaction [35]. This
problem can be overcame by adjusting the proper bisulfite reaction conditions of pH,
temperature and the time of reaction [35].

Direct sequencing of bisulfite treated DNA allows the detection of methylation for each
CpG dinuclotide within the analyzed area, thus is considered as the golden standard for
methylation profiling. Nevertheless, the cost and labor intenseness of this approach is
extremely high for large-scale sample analysis.

Alternatively, the differences between unmethylated and methylated DNA sequence can
be characterized by melting curve analysis. Unmethylated and methylated DNA has
different GC content after bisulfite conversion, presenting varied resistant levels to
melting. To detect the signal of PCR product, fluorescence dyes are used for specific
binding with double-stranded DNA (ds DNA). The fluorescence signal is monitored as
the temperature increases, producing a melting curve to depict the relationship between
fluorescence intensity with the increase of temperature. The characteristics of PCR
product is indicated by the fluorescence peak with a certain melting temperature on the
derivative melting curve. The fully methylated PCR product and fully unmethylated
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DNA shows distinct melting peaks, while a mixture of both may show a complex pattern
with both melting peak characters [36] (Fig. 1.10).
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Figure 1.10, Melting curve analysis on fully methylated, fully unmethylated, and
mixtures of both PCR products for methylation detection [34].
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These sequencing and MCA methods such as combined bisulfite restriction analysis
(COBRA), melting curve analysis methods including methylation-sensitive singlenucleotide primer extension (MS-Snupe), and methylation-sensitive melting curve
analysis (MS-MCA) all reply on the PCR amplification prior to methylation detection.
Methylation-independent PCR primers utilized in these methods allow proportional
amplification of methylated and unmethylated templates. However, the templates of
methylated DNA have higher GC content than unmethylated templates, leading to
different amplification efficiencies and PCR bias for unmethylated product. Although
many attempts are reported to overcome this problem such as increasing the annealing
temperature during amplification and proper primer design [37], the sensitivity of these
methods remains to be improved.

The development of methylation-specific PCR (MSP) in the mid-90s permits the simple
and fast analysis of the DNA methylation status after bisulfite conversion. MSP method
is highly sensitive and specific with designed PCR primer for the amplification of
methylated sequence only. It was reported that MSP was able to detect 0.1% methylated
template in a pool of unmethylated DNA [38]. MSP is also related with high falsepositive rates caused by the incomplete bisulfite conversion and possible contamination
during analysis, which can be alleviated by increasing melting temperature and more
stringent amplification conditions.

The development of quantitative MSP (qMSP) resolves the limitation of MSP based on
real-time PCR (RT-PCR). The amount of initial DNA product can be determined with
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high precision and a wide range. In addition to unknown DNA products, standard
methylated DNA after bisulfite treatment is serially diluted and amplified for standard
curves in separated reactions. Since the quantitative results are relative to the standards,
the absolute quantity of DNA only can be obtained when the absolute copies of the
standards are known.

As an alternative mechanism for cancer development, aberrant gene methylation has been
found in the patterns of hypomethylation for global genome change and
hypermethylation for specific tumor suppressor genes. The DNA methylation profiling
holds promises for the biomarker discovery of cancers and other diseases for early
detection. Nevertheless, these potential biomarkers are relative low abundant in biofluids
or tissues, requiring the developed detection method for gene methylation to be highly
sensitive and specific for potential clinical applications. A large number of target genes
have been identified for colorectal cancer, breast cancer, and hepatocellular carcinoma.
Moreover, the DNA methylation targets are more frequently to be observed as a panel of
multiple genes rather than a single gene, suggesting a direction for improving the
specificity of cancer screening.
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CHAPTER II

QUANTITATIVE ANALYSIS OF BILE ACIDS FOR INFLAMMATORY
BOWEL DISEASES

2.1. Introduction

2.1.1.

Bile acids

Bile acids are produced in the hepatocytes through the oxidation of cholesterol. They are
composed of a steroid structure with side chain terminating in a carboxylic acid and
hydroxyl groups (Fig. 2.1). After conjugating with taurine or glycine in the liver, bile
acids are excreted into gallbladder, released into intestinal tract, reabsorbed in the
terminal ileum, and then back to enterohepatic circulation, leaving a small part entering
into the colon [1,2] (Fig. 2.2). In the terminal ileum, cecum and colon, primary bile acids
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including cholic acid (CA) and chenodeoxycholic acid (CDCA) are metabolized by
bacterial flora through two major reactions: one is deconjugation to produce free bile
acids and taurine or glycine from conjugated bile acids; and the second one is
dehydroxylation to form secondary bile acids deoxycholic acid (DCA), ursodeoxycholic
acid (UDCA) and lithocholic acid (LCA) [3]. The numerous metabolic conversions of
bile acids bring the complexicity of bile acids composition in biological fluids.
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Figure 2.1, Chemical structures of bile acids (a) and internal standard NPA (b)
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Figure 2.2, Bile acids metabolism
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Under the physiological conditions, bile acids are only present at low concentrations in
the peripheral circulation due to the hepatic extraction and intestinal absorption. The
excretion of bile acids from feces stands for 10% -15% of total daily bile acids
production in human. In hepatobiliary and intestinal diseases, the cholesterol metabolism
is disturbed, affecting the synthesis of bile acids and conversion of bile acids in different
biological fluid (serum, bile, urine, and feces). The bile acids quantitative and qualitative
changes in feces provide possible correlation with the development and prevention of
liver diseases and intestinal diseases.

2.1.2.

Inflammatory Bowel Diseases (IBD)

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis
(UC), significantly affects the quality of life of many patients in western world [4]. A
standard surgical procedure called ileal pouch anal anastomosis (IPAA) is usually used
for the treatment of UC. However, patients often develop inflammatory complications of
ileal pouch after the surgery, among which, pouchitis is the most common and nonspecific one [5](Fig. 2.3). The non-specific symptoms of pouchitis bring great challenges
in the diseases diagnosis and management.
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Figure 2.3, IBD and its treatment by IPAA surgery
(http://www.adam.com/)
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The pathophysiology of pouchitis is not completely understood yet, while one of the
important factors could be the bacterial overgrowth in the ileal pouch reservoir [6]. In
hepatobiliary and intestinal disorders, the abnormal cholesterol metabolism affects the
bile acids synthesis, enterohepatic circulation, and biotransformation process, thus
changing its composition in biofluids. Kruis et al. and Natori et al. reported that altered
bacterial conversion of primary to secondary bile acids was related to abnormal intestinal
microflora in UC patients [7, 8]. Therefore, monitoring the change of bile acids profile
through bile acids quantification may serve as a useful diagnostic test for the ileal pouch
diseases developed for the treatment of IBD.

2.2.

Development of a quantitative bioanalytical method for fecal bile acids

2.2.1. Challenges in method development

Due to the complex composition and minor difference between bile acids components,
the quantification of fecal bile acids is challenging. Most of the current methods use gas
chromatography–mass spectrometry (GC-MS) for the analysis of bile acids in feces [9,
10]. Because of the comprehensive bile acids analysis requires the separation of free bile
acids and the conjugated ones, the major disadvantage of the GC-MS approach is the
tedious and time-consuming derivatization and pre-fractionation steps prior to analysis.

LC-ESI-MS is a powerful technique for the simultaneous analysis of multiple bile acids
in biological materials including plasma, serum and urine with high specificity and

56

selectivity [11,12]. One of the challenges is the separation for the dihydroxy C24 bile
acids presenting isomeric structures. The detection of bile acids is often operated in SIM
mode for free bile acids and MRM mode for glycine and taurine conjugates. There was
also a report that utilized LC-ESI-MS to analyze fecal bile acids, but its accuracy and
precision were not reported [13].

Matrix effect is another common problem associated with analysis of a complex
biological sample with mass spectrometry. This phenomenon in ESI was observed when
the target analyte is co-eluted with other bio-fluid components [14]. The endogenous
phospholipids, proteins and fatty acids in the biological samples are the main source of
the matrix effect. The ionization of analyte in mass spectrometry can vary greatly, which
in turn significantly affects accuracy and precision of measurements [15,16]. The affected
signal intensity can be explained as the competition among ions for the limited droplet
surface charge [17]. For example, Scherer et al. reported the matrix effect during the
analysis of bile acids in serum [18]. We also encountered serious matrix suppression
problem during the course of our own analysis of fecal materials.

In this work, we have developed a simple and effective method termed as standard
addition with internal standard (SA-IS) method to overcome the large quantitative errors
brought by matrix effect. Combining standard addition with internal standard, the SA-IS
method takes advantages of both, which compensates matrix effect and variations in
sample preparation and MS detection. In this study, we studied seven bile acids CA,
CDCA,

DCA,

UDCA,

LCA,

taurochenodeoxycholic
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acid

(TCDCA),

and

glycochenodeoxycholic acid (GCDCA) using the SA-IS method along with a simple
sample pretreatment procedure. The sensitivity, accuracy, reproducibility of this method
were evaluated and improved to the acceptable range for the quantitative determination of
bile acids in fecal materials such as pouch aspiration. We expect that the SA-IS approach
developed in this work can be a general method for the quantitative analysis of other
complex samples by LC-ESI-MS, in which the matrix effect exists.

2.2.2. Chemicals and methods

2.2.2.1. Chemicals

CA, CDCA, DCA, UDCA, LCA, GCDCA, TCDCA, N-1-napthylphthalamic acid (NPA),
ammonium hydroxide and ammonium acetate were purchased from Sigma-Aldrich
Chemical (St Louis, MO, USA). HPLC-grade methanol and acetonitrile were also
purchased from Sigma-Aldrich. Deionized water was generated by a Millipore water
purification system (Billerica, MA, USA). Syringes and syringe filters were obtained
from VWR international (Wester Chester, PA, USA).

2.2.2.2. Sample collection

The pouch aspiration used in this study is one kind of homogenous fecal materials.
Diagnostic or surveillance pouch endoscopies, a subspecialty of the Pouthitis Clinic at
Cleveland Clinic (Cleveland, OH, USA), were performed as a part of routine clinical care.
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The project was approved by Institutional Review Board at Cleveland Clinic. Informed
consent was obtained from all patients. Before pouch endoscopy, each enrolled patient
was given one Fleets®enema, and in 5–10 min the patient went to empty the pouch.
Pouch aspiration samples were collected during pouch endoscopy and stored at −20°C.

2.2.2.3. Instrumentation and LC-MS conditions

The LC-MS system consisted of an Agilent 1100 series HPLC (Santa Clara, CA, USA)
and a Waters Micromass Quattro II triple quadrupole mass spectrometer (Manchester,
UK). A Luna C18 column (150 mm, 2mm i.d., 5 μm) with a guard column (40 mm, 2mm
i.d.) from Phenomenex (Torrance, CA, USA) was used for the chromatographic
separation. The mobile phase was a gradient mixture of 10 mM ammonium acetate–
ammonium hydroxide buffer at pH 8.0 (A) and 10mM ammonium acetate in acetonitrilemethanol 3:1 (B). The gradient elution program is illustrated in Figure 2.4. The HPLC
column was first equilibrated with an initial mobile phase of 30% B. The mobile phase
was then increased to 65% B within 6 min and increased to 72% B from 6.1 to 14 min.
Afterward the mobile phase was changed to 90% B in 1 min and maintained for 5 min. At
20 min, the proportion was adjusted back to the initial ratio condition of 30% B and
maintained for 10 min to re-equilibrate the column. During the entire analysis the flow
rate was 200 μL/min. The injection volume was 10 μL and the total run time was 30 min
for each sample including the re-equilibration.
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Figure 2.4, The gradient elution for the separation of bile acids
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Negative ESI mode was adopted for the mass spectrometer operation. A small portion of
flow (50 μL/min) was introduced to the mass spectrometer with a post-column split ratio
of 1:4. Direct infusion of each bile acid at 1 μmol/L and the internal standard (IS) at 10
μmol/L was used to fine tune the mass spectrometry conditions. The ion source
temperature was maintained at 95°C and the capillary voltage was set at 3.0 kV. Nitrogen
nebulization and drying gas were held at 12 and 300 L/h, respectively. Cone voltage was
at 50 V. Detection of bile acids was performed using selective-ion monitoring (SIM)
mode. The deprotonated molecules of the free and conjugated bile acids were recorded at
m/z 375.2 (LCA), 391.3 (UDCA, CDCA and DCA), 407 (CA), 448 (GCDCA), and 498
(TCDCA). Micromass Masslynx (Version 3.3) was utilized for system operation, data
acquisition, and data processing.

2.2.2.4. Stock and working solutions

Stock solutions of each bile acid and IS were prepared at a concentration of 14 mmol/L
by carefully weighting each compound and dissolving them in methanol. Stock solutions
were stored under −20°C. The dilution buffer, 70% mobile phase B, was used for the
preparation of bile acid working solutions at 20, 40, 80, 100, 200, 400, 800, 1000, 1600,
and 2000 μmol/L per compound. The one with the highest concentration was prepared by
mixing equal volumes of seven bile acid stock solutions together; other lower
concentrations were obtained by serial dilution. The IS working solution at 4000 μmol/L
was prepared by diluting the IS stock solution.
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2.2.2.5. Pouch aspiration calibrators and Quality Control (QC) samples

The collected pouch aspiration samples were homogenous and thawed before use. The
blank pouch aspiration lots, which had no detectable ion signals for given bile acids, were
obtained from different IBD patients. The calibrators and QC samples used different two
lots of blank pouch aspiration. Bile acids calibrators of 0.05, 0.1, 0.25, 0.5, 1, 2.5 and 5
μmol/L were obtained by spiking 15 μL bile acid working solutions of 20, 40, 100, 200,
400, 1000 and 2000 μmol/L into 30 μL blank pouch aspiration, respectively. In the same
way, bile acids QC samples of 0.2, 2 and 4 μmol/L were prepared by spiking 15 μL bile
acids working solutions of 80, 800 and 1600 μmol/L into 30 μL blank pouch aspiration,
accordingly. There is a 400 times’ concentration difference between the stock solution
and wanted final concentration of bile acids considering the sample treatment procedures
described in the following section.

2.2.2.6. Sample treatment of calibrators and QC samples for internal calibration

After thawing the pouch aspiration calibrators and QC samples to room temperature from
−20°C, they were homogenized using a mixer. Prior to sample extraction, each aliquot of
45 μL calibrators and QC samples was mixed with 15 μL IS working solution for the
internal standard calibration. For the sample preparation, each of the mixed samples was
added with ethanol to obtain a total volume of 600 μL. The whole mixture was sonicated
by an ultrasonic bath for 15 min. After a centrifugation at 10,000 rpm for 5 min, 100 μL
supernatant was removed and diluted 10 times using the dilution buffer. The solution was
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then filtered using a syringe filter with a pore size of 0.45 μm. Finally, the filtrated
solution was injected into LC-MS system for analysis.

2.2.2.7. Sample treatment of QC and patient samples for SA-IS

Two portions of QC sample and patient sample were needed for each analysis when
applying the SA-IS method. The QC sample analysis required each portion as 45 μL and
the patient samples analysis required each portion as 30 μL. Before the sample extraction,
one portion was spiked with 15 μL IS working solution, and the other was spiked with
both the 15 μL IS working solution and 15 μL bile acid working solution at 800 μmol/L.
The following sample preparation procedure was the same as that described in the section
“Sample Pretreatment of Calibrators and QC Samples for Internal Calibration”.

2.2.2.8. Matrix effect and recovery

For the evaluation of matrix effect in pouch aspiration, the chromatographic peak area
ratios of bile acids to IS in matrix-contained solution were compared with those for the
non-matrix contained solution. The matrix-contained samples were prepared as follows: a
30 μL blank pouch aspiration sample was extracted, diluted, and filtrated by the
procedure described above. Further, bile acids and IS working solution were spiked into
the post-extraction (SPE) solution. The non-matrix contained solutions of bile acids were
the reference samples and were prepared by diluting bile acids work solution using
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dilution buffer. The matrix effect was determined in two different lots of blank pouch
aspiration under three concentration levels: 0.2, 2 and 4 μmol/L.

For the determination of extraction recovery, the chromatographic peak area ratio of bile
acids to IS in the spiking-before-extraction (SBE) solution was compared with that in the
SPE solution. The preparation method of bile acids and IS in the SBE solution was the
same as preparation of QC standards. The recovery was also determined under three
concentration levels: 0.2, 2 and 4 μmol/L.

2.2.2.9. Method validation

After the development of this SA-IS method, we validated it by assessing the linearity,
limit of detection (LOD), lower limit of quantification (LLOQ), and the intra- and interassay precision and accuracy. Bile acids calibration curves were constructed over the
range of 0.05-5 μmol/L. The peak area ratios of bile acids to the IS in the pouch
aspiration sample (y) were regressed against the concentration of spiked standard bile
acids (x).

The LOD and LLOQ samples were prepared by spiking 15 μL bile acid working
solutions with 30 μL blank pouch aspiration. The LOD for bile acids in pouch aspiration
was determined when the signal-to-baseline noise ratio was above 3. The LLOQ was the
lowest concentration of bile acids in pouch aspiration that could be determined within a
precision and an accuracy of 20%.
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Intra-assay precision and accuracy were determined in five replicates of QC samples at
0.2, 2 and 4 μmol/L prepared in the same run. Inter-assay precision and accuracy were
measured in three different runs. The precision was expressed in terms of percentage
coefficient of variation (CV%) and accuracy was expressed in terms of percent relative
errors (RE%).

2.2.2.10. Method application

To test the feasibility of this SA-IS method in fecal material analysis, we determined the
bile acids profiles for a preliminary clinical application. The clinical pouch aspiration
samples were collected from the patients diagnosed as having pouchitis and normal
pouch after IPAA surgery.

2.2.3. Results and discussion

2.2.3.1. Separation of bile acids

A broad range of the bile acids physicochemical properties including PKa and
hydrophobicity, along with the minor difference between some isomeric bile acids, bring
great challenges in bile acids separation. The free and conjugated bile acids have different
PKa range at 3.9 ± 0.1 and 5.0 ± 0.1, respectively [19]. The Log D values of bile acids
distribute from 0 to 4 for all bile acids [20]. Among these seven compounds, UDCA and
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CA are the most hydrophilic bile acids, while DCA and LCA are the most hydrophobic
ones.

The separation of bile acids CDCA, UDCA, DCA, LCA, CA, TCDCA, and GCDCA was
achieved with a Luna C18 column from Phenomenex. The isomeric bile acids CDCA and
DCA were the most difficult to separate. The mobile phase was optimized to achieve
complete separation of these two isomers by using different ratio of methanol, acetonitrile,
and mobile phase additives. The addition of methanol to the organic mobile phase could
sharpen bile acids peaks [21]. The retention times and sensitivity of bile acids were
improved by adding ammonium salts into the mobile phase and adjusting the pH by
ammonium hydroxide at pH 8.0. When the mobile phase is basic, the variation of log P
on the change of pH is the lowest, and consequently the deprotonation of bile acids is
promoted. Three different concentrations of ammonium acetate: 2, 10, and 20 mM were
tested in the mobile phase. We found that 10 mM ammonium acetate yielded the highest
ionization intensity and best separation. With this optimized mobile phase conditions,
gradient elution was applied to separate the analytes within 20 min and to sufficiently
isolate three isomers of UDCA, CDCA, and DCA, as well as other bile acids (Fig. 2.5).
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Figure 2.5, Representative mass chromatograms of bile acids at 0.1 μmol/L and IS
NPA at 10 μmol/L
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2.2.3.2. Matrix effect

The variation of analyte signal after the extraction process for the biological sample is
often contributed by extraction recovery and matrix effect. Recovery variation is mainly
caused by the extraction efficiency, while matrix effect is introduced by co-eluting
interference existing in the extracted solution. When the matrix interference shows higher
proton affinity than targeted analyte, proton is transferred from the ionized analyte to the
interference, causing the lost ion intensity of partial analyte [14]. It has been reported that,
when LC-MS was used to analyze biological samples such as urine and plasma, matrix
effect often occurred and caused deterioration of the precision and accuracy of the
analysis [22-24].

The evaluation of matrix effect during LC-MS analysis usually employed the following
methods: post-column infusion, post-extraction spike, and the comparison of standard
calibration slopes. In this study, the post-extraction spike method and the comparison of
standard calibration curves were employed to assess the matrix effect on bile acids in
pouch aspiration samples.

NPA was selected as IS to normalize MS signal for all bile acids because of their similar
structures and chemical properties [25](Fig. 2.1). After the normalization of MS variation
by the IS, the matrix effect (ME %) was measured by comparing the peak area ratios of
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bile acids to IS spkied in post-extraction solution and with those in dilution buffer
according to [26]:
ME%  (1

RSPE
RDB

)  100%

where RSPE represents the peak area ratio determined in the SPE solution of blank pouch
aspiration and RDB represents the peak area ratio determined in the dilution buffer. The
positive ME% indicates matrix suppression of target analytes; the negative ME%
indicates an enhancement of ionization by sample matrix; and zero of ME% indicates no
matrix effect is present. In addition, we compared the ME% from two different batches
(No.398 and No. 957) of blank pouch aspiration at three concentrations: 0.2 μmol/L, 2
μmol/L, and 4 μmol/L.

In addition, three calibration curves of bile acids were established in the non-matrix
contained solution, matrix contained solution after extracting blank plasma sample lot 1,
and matrix contained solution after extracting blank plasma sample lot 2 for matrix effect
evaluation also. The slopes were compared between three calibration curves.

As shown in Table 2.1, the ME% in sample 398 (except for 4 μmol/L CDCA and DCA)
ranged from 7.6 to 38%, indicating severe ion signal suppression by the pouch aspiration
sample matrix. In sample No. 957 the ME% was even larger. These results were
confirmed in the results from the calibration curves for bile acids in different matrix
solutions (Fig. 2.6). The slopes of calibration curves established in non-matrix contained
solution were higher than that in two different matrix-contained solutions. In addition, the
level of ion suppression resulting from the pouch aspiration matrix varied greatly
69

between different samples. This is not surprising due to the highly complex nature of
fecal materials such as pouch aspiration.
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Table 2.1 Matrix effect determined in blank pouch aspiration
sample No. 398 and No. 957 for bile acids at three concentrations
(n=3)

Bile Acids

CA

CDCA

UDCA

DCA

LCA

TCDCA

GCDCA

Concentration
No. 398 ME (%)
(μmol/L)

No. 957 ME
(%)

0.2

30.6

45.1

2

27.2

41.8

4

11.8

29.9

0.2

23.5

37.2

2

23.9

37.3

4

-1.2

18.9

0.2

29.2

30.9

2

19.2

28.3

4

7.6

21.7

0.2

28.9

37.3

2

21.1

31.7

4

-0.3

21.6

0.2

37.1

47.3

2

24.2

18.4

4

9.7

13.3

0.2

38.0

49.3

2

24.7

36.4

4

8.3

26.7

0.2

35.0

38.1

2

25.1

29.0

4

10.7

22.4
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Figure 2.6, Calibration curves of bile acids: CA (a), CDCA (b), UDCA (c), DCA
(d), LCA (e), TCDCA (f), and GCDCA (g) established in different solution sets:
non-matrix contained solution (● in orange), extracted solution of blank pouch
aspiration lot #1 (▲in blue), and extracted solution of blank pouch aspiration lot
# 2 (■ in purple)
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2.2.3.3. Internal standard calibration

To evaluate the availability of internal calibration for compensating matrix effect and
determining bile acids in pouch aspiration, calibration curves were established from
pouch aspiration calibrators. The calibrator and QC standards were prepared from two
different batches of blank pouch aspiration samples. The QC standards of three spiked
concentrations were measured based on the calibration curves, and the results were listed
in Table 2.2.

For most of the bile acids, the analytical accuracy with the internal standard method was
low considering RE% ranges from -50.4% to 64.6%. These large quantitative errors
resulted from the sample-to-sample variations in the matrix components. More
specifically, such great errors were caused by significant differences between the level of
matrix effect of QC standards and that of calibrators. Therefore, the internal standard
calibration was not suitable for bile acids analysis when the matrix varied among
samples.
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Table 2.2 The accuracy results determined by internal standard method (n=5)

Bile Acids

CA

CDCA

UDCA

DCA

LCA

TCDCA

GCDCA

Spiked
Concentration
(μmol/L)

Accuracy
RE(%)

0.2
2
4
0.2
2
4
0.2
2
4
0.2
2
4
0.2
2
4
0.2
2
4
0.2
2
4

64.6
22.7
21.3
-17.1
-50.4
-23.5
39.8
5.5
-13.6
36.3
7.4
22
15.6
-6.4
5.2
7.4
-17.3
15.4
-19.5
-45.3
20.6
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2.2.3.4. SA-IS method

Several approaches were reported to reduce matrix suppression [15,16,27]. One of most
effective approaches is the use of isotope-labeled analogues as internal standards.
However, the presence of multiple analytes in pouch aspiration requires multiple isotopelabeled internal standards, which are costly and difficult to obtain.

Using appropriate sample extraction procedure is another approach to reduce the matrix
effect. We tried to clean up the co-eluting substance by LLE and SPE. However, since the
hydrophobicity of bile acids has a broad range, it is difficult to develop an LLE method
ensuring low matrix interference and good recovery. Also the large number of lipids and
lysophospholipids, which are similar with bile acids with regarding to structure and
polarity, presents in pouch aspiration, causing the co-elution of bile acids and the
interference when using SPE methods. In addition, the matrix interference, with
significant sample-to-sample variation, could not be removed completely by the same
sample cleanup method. As a result, all of these purification attempts failed to reduce the
matrix effect within 15% for all the bile acids.

Standard addition was another option reported to compensate the matrix effect in LC-MS
analysis [28,29]. It measures the concentration of analyte in an unknown sample by
comparing the response difference between before and after the addition of a known
amount of analyte to that of the original sample. However, standard addition alone cannot
correct the loss of analytes associated with sample preparation. As a result, we
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investigated the SA-IS method that combined standard addition with internal standard to
measure the concentrations of bile acid components in pouch aspiration. The use of
standard addition will eliminate adverse matrix effect on accuracy and precision, while
the use of internal standard will compensate for incomplete extraction and variability in
sample preparation and MS detection.

The SA-IS method is illustrated in Fig.2.7. Cunk represents the unknown concentration of
a bile acid in a pouch aspiration sample; CSA represents the spiked concentration of the
bile acid in the same pouch aspiration after standard addition. The peak area ratios of the
bile acid to IS in the original sample and in standard addition samples are Runk and RSA,
respectively. The peak area ratios are regressed against the concentration of bile acid
spiked in. Cunk is calculated according to:
Cunk 

CSA  Runk
(RSA  Runk )

With the SA-IS method, each pouch aspiration sample was divided into two aliquots: the
first one was spiked with only IS, and the other was spiked with the bile acids mixture
and IS. The validation results showed that the SA-IS is effective in correcting the matrix
effect and more accurate than internal standard method.
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Figure 2.7, Illustration of SA-IS method
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2.2.3.5. Method validation

Linearity: Two requirements are needed when applying the SA-IS: 1) a good linear
relationship between the analyte concentration and according signal response; 2) zero
signal response in the absence of analyte. The linearity were studied by analyzing the
calibrators, which were blank pouch aspiration samples spiked with bile acids and IS.
We observed that calibration curves established by plotting the peak area ratio of analyte
to IS vs. the concentrations of each bile acid were linear within the range of 0.05 μmol/L5 μmol/L with correlation coefficient of 0.9964 - 0.9999 (Table 2.3).
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Table 2.3 Calibration curve results for bile acids spiked in pouch aspiration

Bile Acids

Range
(μmol/L)

Calibration curve of standard bile acid in blank pouch
aspiration sample
slope

y-intercept

correlation
coefficient

CA

0.05-5

4.331

0.063

0.9998

CDCA

0.05-5

3.543

0.016

0.9964

UDCA

0.05-5

5.163

0.012

0.9991

DCA

0.05-5

6.129

0.018

0.9998

LCA

0.05-5

7.782

0.023

0.9988

TCDCA

0.05-5

3.869

0.076

0.9999

GCDCA

0.05-5

3.129

0.048

0.9996
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Sensitivity: The sensitivity of this method was assessed in term of the limit of detection
(LOD) and the lower limit of quantification (LLOQ). For all the bile acids, the LOD was
1 nmol/L using a signal-to-noise ratio of 3. LOD was determined by spiking the bile acid
standards into the blank pouch aspiration samples. The LLOQ was 0.05 μmol/L as the
lowest end of the calibration in this study.

Recovery: We performed the recovery study by determining the peak area ratios of bile
acids to IS in SPE solution and SBE solution. The percent recovery was calculated as:

Recovery% 

  100%
RSBE
RSPE

Independent of the LC-ESI-MS interface and ionization method, the recovery measures
the efficiency of bile acids extraction process during sample pre-treatment. The recovery
of different bile acids varied from 91% to 109.8%, 86.7% to 99.8% and 91.3% to 111.4%
under 0.2μmol/L, 2μmol/L and 4μmol/L levels, respectively (Table 2.4). This showed
that our sample preparation method was adequate to recover bile acids from pouch
aspiration.
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Table 2.4 Recovery of bile acids at three concentrations (n=3)

Bile Acids
CA

Concentration
(μmol/L)

Recovery (%)

0.2

109.8

2

98.9

4

108.5

0.2

91.1

2

86.7

4

97.0

0.2

105.7

2

99.8

4

91.3

0.2

91.0

2

91.5

4

99.4

0.2

102.7

2

92.1

4

107.6

0.2

102.5

2

96.0

4

109.6

0.2

105.8

CDCA

UDCA

DCA

LCA

TCDCA

GCDCA

2

95.7

4

111.4
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Accuracy and Precision: Accuracy in terms of percent relative error was determined
five replicates per concentration for three different QC samples of 0.2, 2 and 4 μmol/L.
The relative error of the SA-IS method was -7.0% to 12.1%, which was within the
acceptable values for FDA guideline ( 20% for LLOQ and  15% for all QC samples)
(Table 2.5). The intra- and inter-assay precision of this SA-IS method were investigated
by five replicating analysis of the QC samples in triplicate run. The CV % ranged from
0.8% to 11.4%. The results have shown that this analytical method is accurate and precise
for the quantification of bile acids in pouch aspiration within the range of 0.05 μmol/L-5
μmol/L.

82

Table 2.5 Accuracy and intra- and inter-precision in the analysis of bile acids in pouch
aspiration by the SA-IS method

Bile Acids

CA

CDCA

UDCA

DCA

LCA

TCDCA

GCDCA

Spiked
Concentration
(μmol/L)

Accuracy
RE(%)
(n=5)

Intra-assay
CV(%)
(n=5)

Inter-assay
CV(%)
(n=3)

0.2

11.1

3.9

4.2

2

12.1

2.7

7.4

4

2.7

5.6

6.2

0.2

9.1

3.8

7.1

2

9.7

2.2

5.8

4

0.4

11.4

11

0.2

-3.1

3.8

4.3

2

7.8

5.8

9.5

4

-1.5

7.6

5.6

0.2

1.3

4.7

7.6

2

8.4

3.8

0.5

4

-2

3.5

5.9

0.2

2.1

4.3

7.5

2

1.9

1.5

2.9

4

-7

4.6

4.6

0.2

7.3

4.4

4.5

2

1.5

3.7

9.4

4

-2.4

4.1

2.8

0.2

8.8

5.7

4.2

2

7.6

3.1

2.8

4

0.7

5.3

4.3
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2.2.3.6. Method application

During the treatment of UC, pouchitis is the most common and non-specific
inflammatory disease developed in the built ileal pouch after IPAA surgery. Currently the
diagnosis criteria of pouchitis are mainly based on clinical symptoms and endoscopic and
histologic value inflammation [5]. To study of the bile acids profile for diseases
developed after IPAA, we applied the SA-IS method to measure the concentration of bile
acids in the pouch aspiration samples from the patients diagnosed as pouchitis (No. 570
and No. 588) and normal pouch (No. 839 and No. 232). The SIM chromatograms
demonstrated that all bile acids peaks were clearly detected and sufficiently separated
(Fig. 2.8). Comparing to normal pouch patients, pouchitis patients showed a relatively
higher concentration of total bile acids and increased ratio of conjugated bile acids (Table
2.6). However, a broader investigation with more pouch aspiration samples will be
required in future studies to determine whether the bile acids profile will become a new
index for the diagnosis of pouchitis.
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Figure 2.8, Chromatograms of bile acids in pouch aspiration sample No. 588
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Table 2.6 Bile acids concentrations in four pouch aspiration samples of patients
diagnosed as pouchitis and normal pouch after IPAA

Found concentrations (μmol/L)
Bile Acids
Class

Bile Acids

Pouchitis
No. 570
No. 588

Normal Pouch
No. 839
114.8

No. 232
143.5

CA

125.5

119.1

CDCA
TCDCA
GCDCA
UDCA
DCA
LCA

84.7
26.9
82.5
20.5
78.2
13.6

124
48.8
69.4
41.5
58.2
35.9

82.2
15.3
18.7
NDa
35.6
23.8

120.2
26.4
12.3
9.6
17.6
37.9

Total Bile Acids (μmol/L)

431.9

496.9

290.4

367.5

Secondary Bile Acids (%)

26

27.2

20.5

17.7

Conjugated Bile Acids (%)

25.3

23.7

11.7

10.5

Primary

Secondary

a Not detected
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The SA-IS method developed in this work can potentially be used to study bile acids
profile in patients with other types of IBD, from whom fecal materials can be collected
during the routine colonscopic surveillance. In addition, the SA-IS method is accurate
and robust, thus it can serve as a reference for researchers to develop other technologies
to profile bile acids in fecal materials.

2.3. Conclusion

Severe matrix effect was observed when quantifying bile acids in pouch aspiration by
LC-ESI-MS. Ionization suppression caused by co-eluting matrix components varied
greatly among samples, and it introduced large errors for the measurement using the
internal standard method. In this study, a standard addition coupled with internal
standard method has been developed and validated to solve the matrix effect problem.
We demonstrated that this SA-IS method could effectively correct the ionization
suppression effect caused by matrix molecules, thus significantly improve the accuracy
of measurements. To the best of our acknowledge, this is the first study utilizing the
combination of standard addition and internal standard to correct matrix effect during the
LC-MS analysis. Compared with existing methods, the SA-IS method involves internal
standard and simple sample preparation. The method was validated to ensure high
sensitivity, accuracy, and precision. We have successfully demonstrated its potential use
in analysis of bile acids in pouch aspiration. The SA-IS method can be a general method
for bioanalysis in the presence of matrix effect.
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CHAPTER III

THE DEVELOPMENT OF A ROBUST AND SENSITIVE LC-MS/MS METHOD
FOR THE QUANTIFICATION OF AN ANTI-CANCER AGENT IN RAT
PLASMA

3.1. Introduction of anti-cancer agent JCC76

In United States, more than 40,000 women die each year from metastatic breast cancer.
Overexpression of human epidermal growth factor receptor 2 (Her2) occurs in about
25%-30% metastatic breast cancer. As a member of ErbB family of receptor tyrosine
kinases [1], HER2 is preferred for ligand binding and the receptor dimerization activated
multiple downstream signaling cascades, which promote cellular proliferation, survival,
migration, invasion, and differentiation. HER2 overexpressed breast cancer has an
increased tendency for metastasis and leads to a relative resistance to same cytotoxic and
hormone therapy [2,3]. Therefore, HER2 tumors are considered to be more aggressive
and often have poor prognosis [4]. Previous research showed that the level of HER2
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expression was closely related to the tumor growth, indicating HER2 as on of the most
valuable targets for breast cancer therapy [5,6].

Nimesulide is a nonsteroidal anti-inflammatory drug (NSAIDs) that inhibits
cyclooxygenase-2 (COX-2) activity. Besides its anti-inflammatory activity, nimesulide
has been reported to inhibit proliferation and induce apoptosis of a variety of human
cancer cell lines including lung, ovarian, and breast cancer [7-9]. Other research
demonstrated that the novel sulfonanilide derivatives of nimesulide significantly
increased the activity in inhibiting breast cancer cell growth in comparison to that of
nimesulide [10-11]. JCC76 {Cyclohexanecarboxylic acid [3-(2,5-dimethyl-benzyloxy)4-(methanesulfonylmethyl-amino)-phenyl]-amide} is a novel compound deviated from
nimesulide without COX-2 inhibitory activity [12]. Recently, this lead compound JCC76
was found to have potent activity against human epidermal growth factor receptor 2
(HER2) overexpressing breast cancer [10].

In the in vitro study, JCC76 was found to dramatically inhibit HER2 overexpression cell
proliferation (i.e., SKBR-3, BT474 and MDA-MB-453 cell lines) [13]. In addition, this
compound induced apoptosis in HER2 overexpressing cells (i.e., SKBR-3), but it was
less active in HER2 negative cells (i.e., MCF-7 and MDA-MB-231), which suggested the
selective inhibition of HER2 overexpressing breast cancer cells [13]. In the in vivo study,
JCC76 significantly decreased the size of breast tumor in the mice xenograft experiments
[14]. Based on these results of pharmacological study, JCC76 demonstrated high
potential to be a target therapeutic agent acting on HER2 positive breast cancer.
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In order to provide insights into the drug developability for targeted breast cancer therapy,
a quantitative method for JCC76 is needed for the further pharmacological and
toxicological studies. To date, no analytical assay for JCC76 has been reported. The low
concentration of JCC76 in blood requires the measurement to be sensitive and specific.
Because of the multiple blood sampling from a single animal model during a short time,
only a low volume of sample can be used for each analysis. In previous studies, the
extraction methods for the class of COX-2 inhibitors, which have similar chemical
structure with JCC76, employed large amount of sample volume (200 – 500 μL) and
solvent consumption (4-8 mL), and complex sample pre-treatment procedures of solid
phase extraction for each analysis [15-17].

In this work, we have developed a single-step LLE method to clean up the sample matrix
and to ensure high extraction recovery. The extraction procedure is fast and simple, and it
consumes less sample volume and solvent. Furthermore, the present study provided a
short time for each LC-MS/MS analysis and high sensitivity with a lower limit of
quantification (LLOQ) of 0.3 ng/mL. Finally, we successfully illustrated the preclinical
application of this method with a pharmacokinetics study of JCC76 in rats.

3.2. Material and methods

3.2.1. Reagents and chemicals
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JCC76 and IS (compound 75) were synthesized according to previously published
procedures (Fig. 3.1) [18]. Their purities were higher than 97%, confirmed by NMR and
HPLC analysis. Methanol, acetonitrile, ethyl acetate, and methyl tert-butyl ether (MTBE)
of HPLC grade and ammonium formate were purchased from Sigma-Aldrich (St. Louis,
MO, USA). N-hexane of HPLC grade was obtained from Pharmco-AAPER (Shelbyville,
KY, USA). Deionized water was purified by Barnstead NANOpure® water purification
system from ThermoScientific (Waltham, MA, USA). Pooled blank rat plasma was
purchased from Lampire Biological Laboratories (Pipersville, PA, USA).
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Figure 3.1, Chemical structures of JCC76 and the internal standard Compound 75
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3.2.2. LC-MS/MS instrumentation

The HPLC system consists of two LC-20AD pumps, a DGU-20A3 degasser, a SIL-20AC
autosampler, and a CBM-20A module (Shimazu, Tokyo, Japan). The chromatographic
separation was performed on a Luna C18 column (2.0 mm × 150 mm, 5 μm) with a guard
column (2 mm × 40 mm, 5 μm) from Phenomenex (Torrance, CA, USA). The mobile
phase was a mixture of aqueous ammonium formate (pH 3.7; 5 mM)-methanol (1:9, v/v).
Isocratic elution at a flow rate of 0.2 mL/min was employed. The injection volume was 5
μL and each run time was 5 min.

The mass spectrometric detection was performed on an AB Sciex QTrap 5500 system
(AB Sciex, Toronto, Canada) with positive electrospray ionization (ESI+). The multiple
reaction monitoring (MRM) function was used to measure the transition of m/z 445 to
366.3 and m/z 439.3 to 360.3 for JCC76 and IS, respectively. The optimized parameters
for detecting JCC76 and IS were set as following: the ion spray voltage was 5500 eV; the
temperature was at 450 C; the heating gas (GS1), nebulization gas (GS2), and curtain
gas (CUR) were 30, 40, and 45 psi, respectively. Compound parameters, including
declustering potential (DP), entrance potential (EP), collision energy (CE), and collision
exit potential (CXP) for both JCC76 and IS, were set at 60, 10, 21, and 10 V, respectively.
Data acquisition and quantitation were performed using Analyst software version 1.4.2.

3.2.3. Preparation of calibration standards and QC samples
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The stock standard solutions of JCC76 and IS were prepared by dissolving each
compound in acetonitrile at 1 mg/mL and stored at -20C. One set of JCC76 working
solutions at 3, 10, 20, 100, 200 and 1000 ng/mL, was prepared by serial dilution from the
stock solution with water-acetonitrile (1:1, v/v), and then used for preparing the
calibration standards. Another set of JCC76 working solutions at 3, 9, 90, and 900 ng/mL
was made in the similar way, and used for preparing QC samples. The working solution
of IS was prepared by diluting the IS stock solution to 50 ng/mL. All of the working
solutions were freshly prepared before use.

The calibration standards were prepared by spiking 5 μL of JCC76 working solutions into
45 μL blank rat plasma to give the final concentration of JCC76 at 0.3, 1, 2, 10, 2 and 100
ng/mL. The QC samples were prepared in a similar way at 0.3, 0.9, 9 and 90 ng/mL,
representing lower limit of quantification (LLOQ), low QC (LQC), middle QC (MQC)
and high QC (HQC) of JCC76 in plasma, respectively. All of the calibration standards
and QC samples were further treated in the same sample preparation procedure described
below.

3.2.4. Sample preparation

Aliquots of 50 μL rat plasma sample, from the calibration standards, QC samples and
pharmacokinetics study samples, were mixed with 5 μL IS working solution (50 ng/mL).
After vortexing for 10 seconds, the samples went through a single step liquid-liquid
extraction with 500 μL of an MTBE-hexane mixture (1:2, v/v). After vortexing for 60 s,
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the mixture was centrifuged at 10,000 rpm for 5 min. Then 420 μL supernatant was
separated, and evaporated using a centri-vap vacuum evaporation system (Labconco, MO,
USA). The dry residues were reconsititued in 42 μL 50% acetonitirle for LC-MS/MS
analysis.

3.2.5. Method validation

Calibration, sensitivity, and selectivity: Calibration curves were constructed by using
the peak area ratios of JCC76 to IS (y) versus concentrations of JCC76 (x) in the
calibration standards. The weighted linear regression was generated by using 1/x as
weighting factor. The LLOQ was determined as the lowest concentration in calibration
curve that can be quantified with the accuracy and precision within 20%. The selectivity
of this method was evaluated by testing the presence of the interfering peak in blank
plasma samples from six different sources.

Matrix effect and recovery: The absolute/relative matrix effect and recovery were
studied at three QC levels: 0.9, 9 and 90 ng/mL. The absolute matrix effect was
determined by comparing the peak area of analyte spiked in the post-extraction solution
of blank plasma with those of standard solution at equivalent concentration. The relative
matrix effect was studied by comparing the peak area ratio of analyte and IS spiked in the
blank plasma post-extraction solution with that in standard solution. The post-extraction
solution was prepared by extracting blank plasma using procedures in section 2.4.
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The absolute recovery was determined by comparing the peak area of JCC76 spiked in
plasma before extraction with that in post-extraction spiked sample. The relative recovery
was determined by comparing the peak area ratio of JCC76 to IS spiked in plasma before
extraction with that in post-extraction spiked sample.

Accuracy and precision: Intra- and inter-assay precision and accuracy were assessed
using QC samples at four different concentrations: LLOQ, LQC, MQC and HQC. Intraassays were carried with five replicates (n=5) for each concentration in the same day,
while inter-assays were performed with five replicates (n=5) in different days. The
precision results were expressed as percent relative standard deviation (% RSD) and the
accuracy results were expressed as percent relative error (% RE).

The dilution QC was also prepared to study the accuracy and precision in cases when
samples concentration was above the highest concentration of the calibration curve. The
dilution QC samples (n=5) contained were prepared by spiking JCC76 into blank rat
plasma at 900 ng/mL, and then were 10 times diluted with blank rat plasma before
extraction. Following the same sample preparation procedures, the dilution QC samples
were analyzed and their concentrations were compared with the nominal concentration.

Stability: The storage stability was investigated with blank plasma spiked with JCC76 at
LQC level (0.9 ng/mL) and HQC level (90 ng/mL) in triplicates going through the
following conditions: sitting in room temperature for 4, 6 and 24 hr, three freeze-thaw
cycles, -20C for 30 days, and post-extraction storage at 4C for 24 hr. For the freeze-
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thaw stability study, the spiked samples were subjected to three freeze (-20C)-thaw
(room temperature) cycles and each cycle was 24 hr.

3.2.6. Pharmacokinetics study

The feasibility of this quantitative method was tested through a pharmacokinetics study
of JCC76 in rats. Male Sprague–Dawley rats (each weight 300 – 350 g) were purchased
from Charles River Laboratories International (Spencerville, OH, USA). The animals
were housed in a 12 h light/dark cycle room with free access to food and water for at least
7 days to adapt to the environment. All the animal experiment procedures were
performed under the guideline approved by Institutional Animal Care and Use
Committee at Cleveland State University.

Before the intraperitoneal(i.p) administration of JCC76 at a single dose of 5 mg/kg,
animals were fasted overnight but with free access to water. Blood samples of 150 μL
each time point were collected from the saphenous veins and femoral veins into
heparinized tubes at 0 hr (before drug administration) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6,
and 8 h after dosing. The blood samples were centrifuged immediately at 10,000 rpm for
5 min in room temperature. The plasma samples were separated and store at – 20 C until
analysis.
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The concentration of JCC76 in rat plasma versus time profiles were analyzed to estimate
pharmacokinetics parameters using WinNonlin® software version 5.2 (Pharsight
Corporation, Mountain View, CA, USA).

3.3. Results and Discussion

3.3.1. Mass spectrometric and chromatographic conditions

In order to optimize the MS parameters, we introduced standard JCC76 and IS in 90%
methanol at 200 ng/mL through infusion into the mass spectrometer at 10 μL/min. The
mass spectra from full positive scan of JCC76 and IS showed the protonated molecules
[M+H]+ with m/z 445.3 and 439.3, respectively. The most abundant product ion after
fragmentation was at m/z 366.3 for JCC76 and m/z 360.3 for IS (Fig. 3.2). The
fragmentation reactions for both compounds were proposed as the loss of SO2CH3 by 79
u. As a result, the ion detection employed multiple reaction monitoring (MRM) mode
with selecting the transition of m/z 445.3 366.3 for JCC76 and m/z 439.3  360.3 for
IS. The collision energy, spray voltage, and ion-spray voltage were fine-tuned to obtain
the highest MS response.
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Figure 3.2, The precursor/product ion spectra and proposed fragmentation
pathways for (A) JCC76 and (B) the internal standard compound 75
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The solubility of JCC76 is poor in water with a predicted high Log D value of 4.86.
Therefore, we chose to use a large portion of methanol in the mobile phase to elute the
compound from a C18 column. Since the addition of organic acids promotes the
protonation of the analyte under positive ESI, several mobile phase modifiers including
formic acid, acetic acid, ammonium formate, and ammonium acetate with different
concentrations were tested to optimize the chromatographic results. We observed that
mobile phase consisting of 5mM ammonium formate-methanol (1:9, v/v) yielded the
highest MS response of JCC76, which increased by 2 folds comparing water-methanol (1:
9, v/v) without any modifier. The retention times were 3.04 min for IS and 3.5 min for
JCC76 by the isocratic elution. Using the above mobile phase, the peaks of analyte and IS
were symmetrical, the sensitivity was improved, and the total run time was controlled
within 5 min.

3.3.2. Sample extraction

PPT has been used extensively for the preparation of plasma samples because of its
simplicity [19]. To simplify our sample extraction technique, the PPT method for plasma
cleaning-up was tested, but matrix suppression of 30%-33% was observed. Adding acetic
acid or formic acid into rat plasma prior to the PPT pre-treatment could relieve the ion
suppression of the analyte by 6-8%. However, it decreased the extraction recovery by 1316%. LLE was reported to be more efficient and to provide cleaner extracts than PPT and
the SPE for sample preparation in most cases [20]. Much effort was put into finding an
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optimal extraction solvent with high extraction efficiencies and minimal matrix effect for
JCC76.

We tested extraction solvents ranged from polar to non-polar, which included ethyl
acetate, chloroform, methyl chloride, diethyl ether, MTBE, and hexane. Among theses
solvents, non-polar ones including MTBE and hexane have much higher extraction
recovery than other solvents for JCC76 (Fig. 3.3), which implies that the non-polar
solvents favored the extraction for hydrophobic compounds. Regarding the matrix effect,
the extraction with MTBE yielded the lowest ion suppression, which agreed with other
reports that suggested MTBE is especially efficient in reducing matrix effect by removing
the phospholipids in plasma [21]. Based on these observations, parallel extraction
experiments based on different ratios of MTBE and hexane mixtures were performed.
Finally, we observed that the optimized solvents mixture consisted of MTBE-hexane (1:2,
v/v) (Fig. 3.4). This LLE method produced reproducible results of matrix effect less than
10% and high recovery above 90% for the extraction of JCC76 from rat plasma. The
extraction procedure is simple, and it uses small amounts of solvent and sample volume.
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Figure 3.3, The comparison of matrix effect and recovery of JCC76 in rat
plasma among different LLE solvents. Each column represents the mean ±
S.D. (n = 3)

106

3.3.3. Method validation

3.3.3.1. Linearity, sensitivity, and selectivity

JCC76 calibration curves were established using double blank (blank plasma sample with
neither JCC76 or IS), zero blank (blank plasma with IS only), and six non-blank
calibration standards at the concentrations of 0.3, 1, 2, 10, 20, and 100 ng/mL. The IS
concentration in zero blank and the calibrations standards was 5 ng/mL. The peak area
ratio of JCC76 to IS (y) versus JCC76 concentration (x) was plotted using 1/x as
weighting factor. The linear regression equation (the slope and intercept in the mean ±
SD) obtained in five different days was y = (0.192  0.002)x + (0.00054  0.0006). The
linearity was excellent over the range of 0.3-100 ng/mL with the correlation coefficients
above 0.9993 for all calibration curves built in different days. Accuracy and precision of
all calibrators were within 15% (Table 3.1). As the lowest concentration on the
calibration curve, the LLOQ was 0.3 ng/mL.

It was sufficient to determine the

concentration of JCC76 in rat plasma for pharmacokinetic study.
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Table 3.1 Accuracy and Precision of JCC76 calibration standards over 0.3 - 100 ng/mL

Nominal
Concentration

Determined
Accuracy %

Precision %

Concentration

0.3

0.29  0.007

-3.3%

3.9%

1

0.98  0.017

-2.3%

1.7%

2

1.89  0.138

-5.8%

7.3%

10

10.15  0.084

1.5%

0.8%

20

19.70  0.310

-1.5%

1.6%

100

100.28  3.581

0.3%

3.6%
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The selectivity was investigated from blank plasma from six different sources. LCMS/MS chromatograms of blank plasma, blank plasma spiked with JCC76 and IS, and a
rat plasma sample after i.p. administration of JCC76 were compared (Fig. 3.4). No
endogenous inferences at the retention times at 3.5 min for JCC76 and at 3.04 min for IS
were found in six different blank plasma samples, indicating high selectivity and
specificity of this method for the analysis of JCC76 in rat plasma matrix.
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Figure 3.4, The MRM chromatograms of (A) blank rat plasma, (B) blank plasma
spiked with JCC76 at LLOQ level (0.3 ng/mL 3.54 min) and IS (5 ng/mL, 3.02 min),
and (C) a real rat plasma sample collected 8 hr after an i.p. administration of 5 mg/kg
JCC76 spiked with IS
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3.3.3.2. Matrix effect and recovery

The matrix effect and extraction recovery was further evaluated at three levels: 0.9, 9,
and 90 ng/mL. As shown in Table 3.2, the absolute matrix effect at three concentrations
ranged from 3.1% to 9.2%, and the relative matrix effect ranged from -6.1% to 4.3%,
indicating no obvious signal suppression or enhancement for the ionization of JCC76 in
rat plasma matrix. The extraction of JCC76 at three levels showed absolute recovery of
89.5% to 97.3% and relative recovery of 105.1% to 106.1% after the IS normalization.
The results indicated that the extraction procedure was not only sufficient to remove the
interference impurities from the sample matrix.
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Table 3.2, Absolute and relative matrix effect and recovery of JCC76 in rat plasma

Matrix Effect

Recovery

Concentration
Absolute
(ng/mL)

Absolute

Relative

Recovery

Recovery

Relative ME
ME

0.9

3.1%

-6.1%

96.9%

106.1%

9

8.8%

3.7%

89.5%

105.1%

90

9.2%

4.3%

97.3%

105.1%
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3.3.3.3. Accuracy, precision, and dilution integrity

As the results shown in Table 3.3, the inter- and intra-assay accuracy and precision were
within  10%, indicating the this method is accurate, precise, and reproducible. Since
some samples containing JCC76 above the highest concentration of calibration curve, we
also investigated the accuracy and precision after ten times dilution of dilution QC by
blank sample matrix. The results showed that the intra- and inter-accuracy of the dilution
samples were -0.1% and 2.1%, respectively. The intra- and inter-precision results were
0.8% and 1.6%. This result suggests that the plasma sample can be diluted and then
analyzed when the concentration of JCC76 is above the upper limit of calibration.
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Table 3.3, Intra- and Inter- assay accuracy and precision of JCC76 in rat plasma

Intra-assay
Nominal

Determined

Inter-assay

Accuracy

Precision

Determined

Accuracy

SD
(ng/mL)

(ng/mL)

%RE

0.3

0.297

-1.1%

0.9

0.870

9

Precision
SD

%RSD

(ng/mL)

%RE

0.004

1.4%

0.301

0.3%

0.010

3.3%

-3.3%

0.010

1.1%

0.915

1.7%

0.072

7.9%

8.63

-4.1%

0.095

1.1%

9.04

0.5%

0.395

4.4%

90

84.2

-6.5%

1.272

1.5%

87.3

-3.1%

2.481

2.8%

900

899

-0.1%

7.483

0.8%

919

2.1%

14.618

1.6%
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%RSD

3.3.3.4. Stability

The results of the stability tests were summarized in Table 3.4. At room temperature,
JCC76 was found to be stable for at least 24 h. The post-extraction stability study of
JCC76 indicated its stability in the reconstitution solvent for at least 24 h. After three
freeze-thaw cycles, the recovery of JCC76 was 78.2 % at LQC and 85.5 % at HQC levels.
The long-term storage stability for JCC76 at -20 C for 30 days was 89.2 % and 79.3% at
LQC and HQC levels, respectively.
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Table 3.4, Stability test of JCC76 in rat plasma

Storage Conditions

At room temperature for 4 hr

At room temperature for 6 hr

At room temperature for 24 hr

Three freeze-thaw cycles

Post-extraction at 4°C for 24 hr

Long-term stability (at -20°C for 30 days)
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Concentration

Recovery

(ng/mL)

%

0.9

99.3%

90

95.3%

0.9

92.3%

90

90.4%

0.9

99.9%

90

99.2%

0.9

78.2%

90

85.5%

0.9

97.6%

90

101.2%

0.9

89.2%

90

78.3%

3.3.3.5. Pharmacokinetic study

The feasibility of this method was tested by the application of a preclinical
pharmacokinetics study in rats. The mean JCC76 concentration in plasma versus time
profile was presented in Fig. 3.5. The maximum concentration of JCC76 (Cmax) in plasma
was 528 ng/mL, which was reached at 0.5 h (Tmax) after dosing. The pharmacokinetics
parameters were estimated through compartmental analysis and the concentration – time
profile was found to fit a two-compartment model. The estimated AUC0-, total body
clearance, and volume of distribution were 1962 (ngh)/mL, 2.5 L/(hkg), and 7.0 L/kg,
respectively.
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Figure 3.5, Mean plasma concentration-time profile of JCC 76 after the i.p.
injection of JCC 76 at a single dose of 5 mg/kg. Each point represents the mean
±S.D. (n = 4)
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3.4. Conclusion

In the presented work we have developed and validated a LC-MS/MS method for the
quantification of JCC76 in a biological matrix for the first time. This method is simple,
sensitive, and specific for the analysis of JCC76 in rat plasma. It used a one-step liquidliquid extraction for sample preparation and a short time for LC-MS/MS analysis. The
LLOQ of this method was as low as 0.3 ng/mL and the accuracy and precision were
lower than 10%. The stability tests were performed under different storage and handling
conditions and the results showed the suitability of this method for high throughput
routine analysis. We have successfully applied this method in the determination of JCC76
in rat plasma for the pharmacokinetics study. This method will be further used in
pharmacokinetics and toxicokinetics studies in animals in the future. It could be valuable
for supporting the new drug investigation and application.
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CHAPTER IV

PROTEOMICS STUDY FOR POTENTIAL BIOMARKER ANALYSIS OF
OVARIAN CANCER

4.1. Introduction

Ovarian cancer is the leading cause of death from gynecological malignancies worldwide.
The lifetime risk of ovarian cancer for women is about 1.6% and the risk increases with
age and deceases with pregnancy. The majority of ovarian cancers tend to present as
advanced stage, resulting in as high mortality rate as 56% [1,2].

The International Federation of Obstetrics and Gynecology (FIGO) staging system
describes the early stage (stage I and II) and advanced stage (stage III and IV) of ovarian
cancer as follows: stage I disease involves one or both ovaries; stage II disease is defined
as the spread tumor limited to pelvis; stage III disease involves the spread tumor with
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peritoneal implants; and stage IV tumor is the distant spread tumor of metastasis [3, 4].
The early diagnosis of ovarian cancer can increase survival significantly. When the tumor
is still confined to the ovary in early stage, detection and surgical removal of cancerous
tissues result in cure for over 90% patients [3]. However, the ovary is not symptomatic in
the stage I and II. Compared to breast, prostate, and colon cancer, ovarian cancer is
anatomically more difficult to be assessed during physical examination due to the
location of the ovary. Therefore, a very promising approach to improve the mortality rate
for ovarian cancer is to discover reliable biomarkers and to develop adequate sensitive
and specific screening test for early detection.

The biomarkers associated with the development of ovarian malignancy have been
investigated in blood, tissue, and other biofluids using DNA microarrays and proteomics.
With advantages in characterizing post-translation modifications of proteins, proteomics
is believed to be one of the most attractive approaches for biomarker discovery. The
technological obstacles of proteomics profiling for ovarian cancer include the lack of
sensitivity of mass spectrometric detection, the mask of low-molecular weight proteins by
the abundant proteins, and the discrimination of ovarian carcinoma from benign tumors.

The only approved serum biomarker CA-125 has been used for remission monitoring of
ovarian cancer, but not for screening. It fails to reach the sensitivity and specificity for a
screening test of early stage ovarian cancer detection. The elevated level of CA-125 was
found in approximately 80%-85% of patients with advanced stage ovarian cancer, but in
only 50% of patients in early stage [5]. In addition, elevated levels of CA-125 are also
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associated with a variety of other conditions including other cancers (pancreatic, breast,
bladder, liver and lung), benign and malignant breast and colon diseases, peritoneal
irritants, and benign gynecologic diseases [6-8]. Nevertheless, new technologies in mass
spectrometry for discovering other novel proteomics markers are emerging, aimed to
improve the sensitivity and specificity of current screening tests.

Due to the dynamic range of proteins present in the serum, high abundance proteins were
removed to increase the possibility of low molecular weight protein detection. Matrixassisted desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) has
been used as an fundamental tool for proteomic study for its efficiency in detecting
peptides as low as 1 femtomole [9]. In addition, there is no mass range limitation for the
MALDI-TOF analysis and it is preferable for fast analysis, allowing 100 samples to be
finished in less than 10 min [10]. For these major advantages, MALDI-TOF-MS was
used for the quick scan of large biomolecules existed in serum samples from ovarian
cancer patients. Our group reported differentiated mass spectra derived from cancer
patient and normal sera by MALDI-TOF-MS analysis for three major peptide peaks of
1260, 1465, and 1545 Da [11] (Fig. 4.1).
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Figure 4.1, Previous reported analysis on MALDI-TOF-MS pattern for
ovarian cancer patient and normal control samples [11].
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Based on these previous findings, comparative analysis of low molecular weight protein
profiling was further preformed by LC-MS/MS in this work. Several sets of samples from
patients with ovarian carcinoma, benign tumors, and healthy normal controls were
examined to identify carcinoma-associated proteins or peptides as valuable biomarkers
for ovarian cancer progression. One of the major MS peaks, which discriminated normal
control with cancer patients in MALDI-TOF scanning, was defined by LC-MS/MS
analysis. The developed LC-MS/MS method greatly improved the reproducibility in
peptides profiling. In addition, the protein fractionation method was refined in terms of
higher extraction efficiency and less impurities. At last, the discovered biomarker was
validated in benign and carcinoma samples for the improvement of early detection.

4.2. Materials and Methods

4.2.1. Materials

Acetonitrile and chloroform of HPLC grade, TFA, and formic acid were purchased from
Sigma-Aldrich Chemical (St Louis, MO, USA). Deionized water was generated by a
Millipore water purification system (Billerica, MA, USA). Phosphate-buffer saline (PBS)
solution was purchase from BIO-RAD (Hercules, CA, USA).

4.2.2. Patient samples
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Human serum samples from healthy individuals were purchased from Sigma-Aldrich (St
Louis, MO, USA). The serum samples from patients diagnosed with advanced stage
ovarian cancer of carcinoma (N=40) and benign diseases (N=20) were obtained from
Gynecologic Oncology Group (GOG) tissue bank (Buffalo, NY, USA). Among the forty
carcinomas samples, there were twenty papillary serous carcinomas, ten mucinous
carcinomas, five endometrioid carcinomas, and five clear cell carcinomas; As the twenty
benign samples, there were ten serous benign, five mucinous benign, and five other
benign. This project was approved by the Institutional Review Board at Cleveland State
University.

4.2.3. Serum peptide fractionation

The low molecular weight peptides were separated from the abundant proteins in serum
by protein precipitation. An aliquot of 40 μL serum was mixed with 1 mL 90% methanol
in water. After vortexing for 1 min, the mixture was centrifuged at 10,000 rpm by a
Beckman Coulter AllegraTM X-22R Centrifuge for 5 min to precipitate the proteins. The
clear supernatants were removed and then evaporated to dryness by centri-vap vacuum
evaporation system (Labconco, MO, USA). The dry residues were re-dissolved in 400 μL
water. Afterward, the solution was cleaned by adding 200 μL chloroform for liquid-liquid
extraction. The chloroform phase and aqueous phase were well mixed by vortexing for 2
min. The mixture was centrifuged at 10,000 rpm for 5 min and the upper layer was
carefully removed. After evaporating and concentrating the sample to 60 μL, an aliquot
of 10 μL solution was injected to the LC-MS/MS system for analysis.
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4.2.4. Online peptide trap setup

Prior to the micro-flow LC separation, the injected peptide sample was cleaned and desalted by an online peptide trap setup. As illustrated in Fig. 4.2, at the sample loading
position, the trap peptide cartridge (CapTrap, Michrom) was connected with sample
injector; at sample elution position, the peptide trap was connected with elution buffer
pump and capillary HPLC column. After the sample was loaded into the peptide trap in
10 min, the column switch was changed to sample elution position. The switched elution
buffer eluted the sample from the trap to the HPLC column.

129

Figure 4.2, Online peptide trap setup
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4.2.5. Serum protein analysis by LC-MS/MS

The micro-LC-MS/MS system consisted of an Aglient 1100 HPLC, an online-extraction
system, and a Bruker HCT 3000 plus ESI IonTrap Mass Spectrometer. The
chromatographic separation of peptides was carried out on a Vydac C18 capillary reverse
phase HPLC column (100 mm × 300 μm ID, 5 μm) at room temperature (23°C). The
mobile phase used 0.1 % formic acid in water: acetonitrile (99:1, v/v) as aqueous phase A
and 0.1% formic acid in water: acetonitrile (1: 99, v/v) as organic phase B. The following
gradient elution program was applied for all the peptide analysis: at the beginning of LC,
2% B was hold for 10 min, then increased to 90 % B in 70 min, following by maintaining
90% B for 20 min, and at last returned to 2% B for 10 min for re-equilibration. The flow
was maintained at 5 μL/min through the analysis.

The mass spectrometer was operated in positive ESI mode. MS/MS data were acquired at
a scanning mode of standard-enhanced at a range of 350- 1500 m/z. The nebulization gas,
drying gas, and dry temperature were set as: 11 psi, 5 L/min, and 300 °C, respectively.
The tandem MS data were used to search matched peptide fingerprints against NCBInr
protein database by Mascot Program (http://www.matrixscience.com). The following
searching parameters were applied: no trypsin, no taxonomy or modification, peptide
mass tolerance is ± 1.0 Da, MS/MS tolerance is ± 0.5 Da, all possible charge states (i.e. +
1, +2, and +3), and a mass window between 0 and 100 kDa. To reduce the number of
false-positive signals, only significant hits with at least 4 matching peptide masses were
considered as final results.
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4.3. Results

4.3.1. Identification of differentially expressed low molecular weight peptides

Based on the results of MALDI-TOF-MS pattern analysis reported previously [11], the
clinical serum samples of 20 ovarian caner patient and 18 normal healthy controls
generated a panel of biomarkers. By comparing the typical MS pattern, significant
differences were observed regarding three peaks with the following m/z: 1465 Da, 1260
Da, and 1535 Da [11]. However, this method is poor in reproducibility and is not able to
identify the peptide with corresponding MS spectra.

To compensate for this disadvantage, ESI-MS was used for improving the reproducibility
in this study since no crystallization process during ionization is involved in ESI
compared to MALDI. The mass spectrometer generated the spectra of both precursor
ions and fragmentation ions, which were further analyzed by the computer to search for
matching protein information in the database. Since HPLC was often necessary to
separate the complex proteomic sample prior to the MS analysis, we conducted capillary
LC to analyze pre-fractionated serum samples from ovarian cancer patient group and
normal control group.

Initially, the mixture of six patient samples and the mixture of six ovarian cancer patient
samples were analyzed. From the resulting chromatograms, we noted that the major
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difference between these two sample mixtures was a peak appearing at 42 min in cancer
group but not in control group (Fig. 4.3). In the averaged MS spectra generated by this
characteristic peak, the double charged MS peak of m/z 733 had the highest signal
intensity. This finding was consistent with the result from previous MALDI-TOF-MS
analysis, which showed the most abundance peptide peak at 1465 Da.
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Figure 4.3, Differentiated LC-MS/MS chromatograms from ovarian cancer
group (top) and control group (bottom)
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Further, the mascot database searching was applied using the MS/MS peptide data
acquired from the ovarian cancer sera sample. The matched peptide information was
identified as des-alanine fibrinopeptide A (des-alanine-FPA) with the sequence of
DSGEGDFLAEGGGVR. Des-alanine-FPA is derived from FPA by losing an amino acid
and its molecule weight is 1465 Da. Interestingly, we did not find the intact FPA of 1535
Da in neither the cancer patient samples nor in the normal healthy individuals. By
carefully looking at the results of Mascot searching, we found that the des-alanine-FPA
fragment fingerprints matched up with the MS spectra of peak eluting at 42 min in
ovarian cancer serum sample (Fig. 4.4).

135

Figure 4.4, The MS spectrum of chromatographic peak eluting at 42 min,
with matched MS information with des-alanine-FPA
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4.3.2.

Protein fractionation method by organic solvent precipitation

Previously our group has successfully removed the abundant proteins by utilizing 80%
acetonitrile solution and obtained better prefractionation results compared to centrifugal
ultrafiltration. To further optimize this sample preparation method, we compared the
signal intensity of des-alanine-FPA in the supernatants after 80% acetonitrile
precipitation and 90% methanol precipitation. The results indicated that 90% methanol
precipitation yielded higher intensity of des-alanine-FPA and its fragments in the MS
spectrum, suggesting a better recovery of this biomarker.

The MS and MS/MS spectra were examined from the whole gradient program to find out
when des-alanine-FPA was mainly eluted. This potential biomarker was separated from
other hydrophobic components, which were mainly eluted out at the end of elution
program with high percentage of organic phase. However, the full scan chromatogram
indicated that the intensity of des-alanine-FPA was much lower than these components.
These hydrophobic components may overload the reverse phase column and decrease the
efficiency of chromatographic separation after a few continuous injections. To prevent
the reduction of column robustness, we added a liquid-liquid extraction procedure to
remove hydrophobic components after organic solvent precipitation.

The supernatants after 90% methanol precipitation were subjected to a liquid-liquid
extraction method using chloroform as the extracting solvent. By comparing the
chromatograms with and without chloroform extraction, the MS total ion chromatograms
of ovarian cancer serum sample showed much lower intensity of hydrophobic
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components, but without much effect on des-alanine-FPA level (Fig. 4.5). In addition, we
did not observe any decrease in the resolution and intensity of the differentiated
chromatographic peaks in five continuous injections. It proved that the liquid-liquid
extraction method was effective to reduce the complexity of serum by removing partial
hydrophobic components.
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Fig. 4.5, Improvement of chromatograms by adding a chloroform-water
extraction procedure into the sample preparation. Blue line indicate sample
without chloroform-water extraction and black line indicate sample with
chloroform-water extraction.
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4.3.3.

LC-MS/MS analysis of different sample sets

Given the finding of des-alanine-FPA as a potential biomarker by LC-MS/MS analysis,
we further evaluated this biomarker in each serum sample of the patients with carcinoma,
patients with benign conditions, and healthy control. The tandem MS information for
each sample was processed and used for the searching of the des-alanine-FPA
fingerprints.

The criteria to confirm whether des-alanine-FPA exists in different samples include the
MS/MS database search and the elution time at 42 min. Des-alanine-FPA peak was
predominantly found in both the benign and carcinoma groups. Analysis of 20 benign
samples yielded detectable des-alanine-FPA peak in 16 samples with the percentage of
80%. Among the 40 carcinoma samples subjected to analysis, 37 samples were observed
with des-alanine-FPA peak, indicating the sensitivity of this biomarker as 93%. With
regarding to the control group, we observed that three samples (N=20) showed desalanine-FPA signal and all other samples had negative results, suggesting a good
specificity result of 85%.

Considering half of the malignant tumors are transformed from the pre-existing benign
cysts, the up-regulated des-alanine-FPA appearing in a high percentage of benign set is
not surprising. However, when comparing the peak area or signal intensity of desalanine-FPA peak in the benign and carcinoma sets, we did not observe any significant
difference on its expression levels to discriminate these two sets. This is possible if des-
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alanine-FPA is not only involved in the slow growth of pre-malignant lesions before
carcinogenesis, but also is associated with the fast transformation of normal ovary to
carcinoma.

4.4. Discussion

In this study, we demonstrated a LC-MS/MS method for the low molecular serum protein
profiling in the biomarker discovery of ovarian cancer. One of the obstacles for protein
biomarker discovery in serum is the dynamic range of protein components. To overcome
this problem, extensive pre-fractionation steps were usually needed to increase the
likelihood of low abundance biomarker detection. It has been reported that organic
solvent precipitation was used to extract low molecular weight protein in human serum
samples [12]. Compared to other methods, organic solvent precipitation method is simple,
convenient, and processes high recovery for low abundance peptides.

The sample pretreatment method utilized in this work was modified based on previous
reports. It improved reproducibility and sensitivity by reducing the hydrophobic residues
in the serum sample solution after the depletion of high abundance proteins. The
developed LC-MS/MS method showed that the chromatogram of serum low molecular
weight peptides differentiates from ovarian cancer patients to healthy control in a major
marker peak. Further, this peak was characterized as des-alanine FPA, which is derived
from fibrinopeptide by losing an amino acid of alanine.
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Fibrinopeptide A (FPA) is generated from fibrinogen by thrombin during blood
coagulation. Thrombosis and disseminated intravascular coagulation are common
complications of cancer, and such a procoagulant state in cancer arises mainly from the
capacity of tumor cells to express and release procoagulant factors. It has been reported
that FPA related peptides were up-regulated in different type of cancers including ovarian
cancer [13-16]. In addition, there was finding of elevated phosphor-FPA as posttranscription modification in serum of advance staged ovarian cancer samples [13]. These
findings revealed a high degree of biological relevance between cancer and fibrinogen
fragments. However, the mechanism of high level des-alanine-FPA and its correlation
with ovarian cancer has not been reported yet. It is essential to carry out a careful followup validation using rational and rigorous methodology for ovarian cancer biomarker
discovery.

In the validation of des-alanine-FPA level in the sample with different sets of ovarian
cancer diseases, we found that both benign and carcinoma sets had up-regulated desalanine-FPA expression compared to normal control. The challenge of differentiating
benign tumors with malignant carcinoma for ovarian cancer screening remained in this
work. We have not found any relation between the level of this biomarker to define
different disease states such as benign and carcinoma.

Serum was used as the sampling source in this study because it contains the circulating
proteins and peptides shed from cancerous cells and tissues into blood. Compared to
plasma, it is less complex due to the coagulation process and the removal of clotting
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factors during specimen collection. Serum is generally used as an acceptable starting
material for many diagnostic assays and proteomics investigations. However, the serum
sampling process usually requires the coagulation process of whole blood for 30-45 min,
which initiates a cascade of enzymes reactions such as the formation of solid fibrin by
serine proteases. During this clotting process, FPA is removed from the n-terminal
segment of the alpha chains of fibrinogen by the thrombin. We were concerned that the
FPA level and especially des-alanine-FPA level could be affected by clotting process of
serum sampling. Variability introduced through sample collecting and storage can be
misinterpreted as des-alanine-FPA level changes resulting from ovarian tumorigenesis.

Consequently, further study should be carried out in examining whether the specimen
sampling and storage as well as our current sample preparation method affect the desalanine-FPA level. More importantly, the verification of the des-alanine-FPA level in the
plasma is essential to move this work forward. Compared to serum, the sample source of
plasma avoids the specimen-to-specimen variation of clotting extent and duration and
could better represent real blood proteomes.
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CHAPTER V

COMPREHENSIVE ANALYSIS OF TUMOR-ASSOCIATED DNA
METHYLATION IN HEPATOCELLULAR CARCINOMA

5.1. Introduction

Hepatocellular carcinoma (HCC) is the one of the most aggressive malignancies with the
third mortality among cancer worldwide [1]. Highly prevalent in Asia and Africa, HCC is
recently reported to be on the rise in many developed countries including United States,
Japan, and Western Europe [2]. The clinical management of HCC, depending on its stage,
includes curative approaches such as resection, orthotopic liver transplantation, local
ablation, radioembolization, and sorafenib treatment [3]. Despite significant advances in
HCC management, the survival rate of HCC is low due to its poor diagnosis and
prognosis, high recurrence, and resistance to chemotherapy and radiotherapy [4].
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The major etiological risk factors of HCC for cancer development have been well
understood. These factors include hepatitis virus infection, chronic alcohol consumption,
liver cirrhosis, and aflatoxin intake [5,6]. However, the majority of HCC were detected in
non-resectable advanced stages, which prevents potential curative treatments.

The early diagnosis of HCC presents a lot of challenges since the imaging techniques
such as CT and MRI scan are not adequate to distinguish HCC with long-term liver
cirrhosis [7]. The most commonly used tumor biomarker α-fetoprotein (AFP) is helpful in
the surveillance tests, but its use is also controversial because of lacking diagnostic
accuracy and sensitivity [8]. Other serum biomarkers such as lectin-bound AFP, or descarboxy-prothrombin (DCP) have large limitations because they are not consistent or
particularly precise for the early diagnosis of HCC [9]. Therefore, it is urgent to develop
novel biomarkers for the early detection of malignancy of hepatocytes for better
screening tests.

The carcinogenesis for HCC development involves complicated genetic and epigenetic
changes. Genomic alterations such as gene mutations, chromosomal amplifications and
deletions, and unstable genomics were closely associated with HCC [10,11]. In addition,
epigenetic alterations, including DNA methylation, histone modification, and altered
expression of chromatin-modifying enzymes were also frequently observed in malignant
transformation of hepatocytes as an alternative pathway [12]. Aberrant gene methylation
has been well documented as the best-known epigenetic event in different cancers
including HCC [13,14]. When DNA methylation occurs in CpG dinucleotides, a methyl
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group from S-adenosyl methionine (SAM-CH3) is added at the carbon five position of the
cytosine ring through covalent bond (Fig. 5.1). This reaction is catalyzed by DNA
methyltransferases 1, 3a, or 3b (DNMT).
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Figure 5.1, Cytosine methylation catalyzed by DNMT
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In cancers, global hypomethylation causes the instability of chromosomes and local
changes of promoter methylation (hypermethylation) of CpG islands in tumor suppressor
genes lead to transcriptional silencing [15,16]. Besides the direct inactivation of tumor
suppressor genes, DNA hypermethylation can also block transcription factors and silence
DNA repair genes, resulting in the loss of downstream gene functions and the
accumulation of genetic lesions [17].

In HCCs, a growing number of genes with aberrant DNA hypermethylation have been
identified. Epigenetic silencing of the tumor suppressors RASSF1A and p16 (CDKN2A)
were frequently reported in previous studies. Hu L et al. detected the promoter
hypermethylation of RASSF1A in both serum and tissue DNA in HCC [18]. Similarly,
Formeister et al. reported the increased methylation of RASSF1A, p16 (CDKN2A), APC,
GSTP1, and RIZI in tumorous tissues comparing with adjacent non-tumorous HCC
tissues [19]. In addition, this phenomenon has been observed in the non-cancerous
cirrhotic tissues of HCC patients, supporting that the hypothesis that epigenetic
inactivation is an early event of HCC [20]. These findings help the understanding of
hepatocarcinogenesis in early stage and support the potential biomarker discovery for
early diagnosis through methylation alterations.

The RASSF1A gene is one major isoform of Ras-Association Domain Family 1
(RASSF1). It maintains the genomic stability and modulates a broad range of cellular
functions including apoptosis, cell motility and invasion for normal cell functions [21].
The expression of RASSF1A is ubiquitous in non-cancerous tissues, but is reduced in
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cancer cell lines and tissues. Mice with knocked out RASSF1A gene has the tendency to
develop tumors, correlating impaired RASSF1A expression with tumorigenesis [22]. The
lost of RASSF1A function has been found in 37 tumor types due to the promoter
methylation [23].

P16 is a cyclin-dependent kinase inhibitor (cdki) with the biochemical ability to form a
complex with cdk 4-6. This binding process inhibits cell cycle progression and tumor
progression. P16 gene mutation, promoter methylation, and deletion are counted as the
causes of its frequent inactivation [24]. Loss of p16 expression is not only reported in
tumor development, but also for the prognosis of tumor progression [5,26].

In this study, we compared the DNA methylation status in paired HCC and noncancerous liver tissues for a panel of 21 tumor-related genes. Among these selected genes,
p16, RASSF1A, E-Cadherin, MSH2, CCND2, SEMA3B, SPINT2, SFN, MYC,
MAGEA3B, FHIT, and MGMT were reported to have methylation rates higher than 40%
for HCC [19, 27-30]. The other 9 genes: p14, p15, GATA4, NDRG4, OPCML, SEPT9,
SFRP2, TFPI2, and ALX4 were documented to have elevated methylation in colon
cancer tissues [31-34]. Using bisulfite deamination treatment and methylation-specific
polymerase chain reaction (MSP) method, we obtained the distinct HCC methylation
profiles and evaluated their combinational use for the detection of HCC.
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5.2. Materials and methods

5.2.1. Collection of clinical tissue specimen

We analyzed 80 tissue samples, consisting HCC and paired non-HCC liver tissues as
control, from 40 patients who underwent curative resection surgery between 2001 and
2007. All patients were subjected to pathological diagnosis and classification for different
stages. Informed consent was obtained before the study from each patient. A summary of
the clinicopathological features is listed in Table 5.1. For all patients, liver tissue samples
were collected from the cancerous and the adjacent non-cancerous surgical margin. The
adjacent tissues included 16 cirrhotic samples and 24 normal samples. All of these tissues
were stored as formalin-fixed paraffin-embedded (FFPE) samples.
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Table 5.1, Clinical and pathological characters of 40 HCC patients
involved in this study
HCC patients

NO. of Patients

n=40
Male

32

Female
Female

8

Age (average ±SD)

50.5±8.2

Etiology
HBV

50.5±8.2
8

Tumor size

>5cm
<5cm

16

Yes

24

No

16

Yes

25

No

15

I

2

II

17

II-III

8

III

13

24

Cirrhosis

Nodules

Stage
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5.2.2. DNA isolation from liver tissues

Since all the tissue samples were fixed by formalin and embedded by paraffin, they were
cut into 5 μm sections prior to xylene extraction. Every 6-7 sections of FFPE samples
were incubated with 1.5 mL of xylene and vortexed for 30 min. Followed by the
centrifugation at 10,000 rpm for 5 min, the supernatant was removed to a clean
Eppendorf tube. These steps were repeated for 3 times by adding ethanol into the pellet to
remove the residual xylene. At the end, the resulting tissue pellet was collected after the
evaporation of ethanol residue.

Genomic DNA automated extraction was performed on the Maxwell® 16 Instrument
(Promega, Madison, WI) with Maxwell® 16 DNA Purification Kits. Tissue pellet was
lysed, purified, and washed by cell lysis solution, MagneSil PMPs, and wash buffer,
respectively.

5.2.3. Sodium bisulfite conversion

Prior to sodium bisulfite conversion, DNA concentration was quantified by RT-PCR
amplification. Standard unmethylated and methylated genomic DNA was purchased with
CpGenome DNA modification Kit (Millipore, Billerica, MA) for establishing standard
curve. Different concentration of standard DNA were obtained by serial dilution and then
amplified with the β-actin (ACTB) primer: 5’ GGCGGCACCACCATGTACCCT 3’ and
5’ AGGGGCCGGACTCGTCATACT 3’. Sample DNA concentration was calculated
154

utilizing the standard calibration curve of cycle numbers and log concentration. Based on
these results, the final genomic DNA concentrations of all samples were normalized
within the same concentration through dilution adjustment.

Sodium bisulfite reaction was performed on cancerous, adjacent cirrhosis, and normal
control DNA samples as well as standard unmethylated and methylated DNA samples
using the EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA). Briefly, the
bisulfite reagent was prepared as 5.5 mol/L sodium bisulfite in the mixture of M-Dilution
buffer and M-Dissolving buffer (6:1, v/v). Every 100 ng DNA samples were mixed with
50 μL bisulfite reagent. The reaction took 150 min in the following program: 0-10 min at
95 °C, 10-150 min at 64 °C, and then cool down to 4 °C at the end of the reaction. The
modified DNA sample was then desalted using KingFisher Flex Magnetic Particle
Processors (Thermo Scientific, Asheville, NC). The whole purification consisted of
sample binding, desulfonation, binding buffer wash, ethanol wash, and elution. The
sample binding process utilized 200 μL EZ beads for each sample. The desulfonation step
used 0.2 mmol/L NaOH in PEG binding buffer, and the ethanol wash used 80% ethanol
and 100% ethanol with or without salts. At the end, the converted DNA sample was
eluted in 10 mM Tris buffer and store at -20 °C for the further use.
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5.2.4. DNA methylation analysis

MSP amplifications of 21 genes including p16, RASSF1A, MSH2, CCND2, SEMA3B,
SPINT2, SFN, MYC, MAGEA3B, FHIT, E-Cad, MGMT, p14, p15, GATA4, NDRG4,
OPCML, SEPT9, SFRP2, TFPI2, and ALX4 were performed on MJ Research Chromo4
Real Time PCR Instrument (Bio-Rad, Hercules, CA) and LightCycler 480 (Roche
Diagnostics; Switzerland). The primer sequences of each locus for MSP were described
in Table 5.2. The reaction mixture included 1 μL bisulfite-modified genomic DNA, 4 μL
primer solution at 5 μmol/L, and 5 μL Type-it® HRM master mix (contains DNA
polymerase, EvaGreen dye, optimized concentration of Q-solution, dNTPs, and MgCl2)
(Qiagen,Valencia, CA) for a total volume of 10 μL. The following PCR program was
applied: 95 °C denaturing for 10 min and 50 cycles of 95 °C for 45 s, annealing
temperature for 30 s, and extension at 72 °C for 45 s.
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Table 5.2, The MSP primer sequences of 21 genes

Gene

MSP primer 5'-3'

Annealing
Temperatu
re (°C)

F: TTATTAGAGGGTGGGGCGGATCGC

p16 (INK4A)

R: CCACCTAAATCGACCTCCGACCG

66

F: GTGTTAACGCGTTGCGTATC

RASSF1A

R: AACCCCGCGAACTAAAAACGA

57

F: GGCGGATTT TAT CGTAGTCG

CCND2

R: CTCCACGCTCGA TCCTTCG

62

F: TGGTTAGGCGGGGTATTTTC

SEMA3B

R: TCAACAATAAAAACGAAAACG

58

F: CGGGCGTTTTTATATTGAAGGTTC

SPINT2

R: ACGCCACCAACCGTTAAAATCTCG

60

F: TAGAATTGGATCGGGGTAAA

MYC
R: CGACCGAAAATCAACGCGAAT

SFN

F: TGGTAGTTTTTATGAAAGGCGTC

(has-mir-219-2)

R: CCTCTAACCGCCCACCACG

57

58

F: TTTGTTCGGAATTTAGGGTAGTATC

MAGEA3

R: GTCGCTCGTTACTCAAAACG

60

F: TCG TGG TCG GAC GTC GTT C

MSH2

R: CAA CGT CTC CTT CGA CTA CAC CG

60

F: GAAGGTAGGGGCGGGGAGGTAAGTT

FHIT

R: CGTAAACGACGCCGACCCCACTA
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68

Gene
E-Cadherin

MSP primer 5'-3'
F: TAATTAGCGGTACGGGGGGC

Annealing
Temperature
(°C)
66

R: CGAAAACAAACGCCGAATACG

MGMT

F: ATTTGGTGAGTGTTTGGGTCGTTTC

57

R: AAAACGCACCTAAAACTCGCCC

OPCML

F: CGTTTAGTTTTTCGTGCGTTC

62

R: CGAAAACGCGCAACCGACG

P15

F: GCGTTCGTATTTTGCGGTT

58

R: CGTACAATAACCGAACGACCGA

SFRP2

F: GGGTCGGAGTTTTTCGGAGTTGCGC

60

R: CCGCTCTCTTCGCTAAATACGACTCG

TFPI2

F: TTTCGTATAAAGCGGGTATTC

57

R: ACGACCCGCTAAACAAAACG

ALX4

F: CGTTCGCGTTTTCGTTCGTCGTTTGC

58

R: ACGACGAACCCTCCCGACTCTACG

GATA4

F: AGGTTAGTTAGCGTTTTAGGGTC

60

R: ACGACGACGAAACCTCTCG

NDRG4

F: TTTAGGTTCGGTATCGTTTCGC
R: CGAACTAAAAACGATACGCCG
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5.2.5. Specificity and sensitivity of MSP

The specificity of the MSP assay was evaluated by detecting the bisulfite-modified
standard unmethylated DNA and methylated DNA through high-resolution-melting
(HRM) analysis repeatedly. The melting temperatures for each gene were recorded as
reference for the patient sample analysis. Sensitivity of MSP was determined by mixing
bisulfite-modified standard methylated DNA (1%) with standard unmethylated DNA
(99%) together.

5.2.6. Quantitative methylation analysis

The quantitative methylation analysis was carried out on MJ Research Chromo4 Real
Time PCR Instrument. Bisulfite-converted standard DNA sample of known concentration
was serial diluted and amplified using bisulfite-converted ACTB primer. The standard
curve prepared from this step was used for determining reference quantity of total
DNA(Qtotal) amount for each patient sample. The amplification condition was as
following: 95 °C denaturing for 10 min, 50 cycles of 95 °C for 45 s and 60 °C annealing
for 30 s, and extension at 72 °C for 45 s. Patient samples that were negative for ACTB
gene amplification were exclude from the study.

The methylated DNA reference(QM) was determined by constructing the standard curve
of bisulfite-converted standard methylated DNA in serial concentrations. The conditions
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for the amplification were using the MSP primer and specific annealing temperature. In
this case, only the converted methylated DNA can be amplified.

5.3. Results

5.3.1. Specificity and sensitivity of MSP method

The specificity of the MSP methods on 21 genes was evaluated using standard
unmethylated DNA as negative control and methylated DNA as positive control to ensure
the completion of bisulfite conversion. In addition, two blank samples, one from the
blank control added before the bisulfite conversion and the other added before the PCR
reaction, were used to account for false positive. As shown in Fig. 5.2, this highly
specific test on the SFN gene was illustrated in the PCR amplification and the subsequent
melting curve analysis for standard methylated DNA and unmethylated DNA as well as a
blank control. The selected primer and optimized PCR conditions ensured that only
methylated DNA after bisulfite conversion could be amplified for all genes. The
specificity of these MSP methods is high for all 21 genes.
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A.

B.

Figure 5.2, The amplification results of standard methylated DNA, 1%
methylated DNA, standard unmethylated DNA as negative control, and blank
control are shown in RT-PCR (A) and melting curve analysis (B).
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The sensitivity of the MSP methods was assessed by mixing 1% standard methylated
DNA and 99% standard unmethylated DNA together. Repeated amplifications of the
mixed sample were performed by RT-PCR. For most genes, the MSP methods could
detect 1% methylation to ensure enough sensitivity of tests (Fig. 5.2).

During the patient sample MSP analysis, control samples including negative and positive
control, and two blank samples, as well as 1% standard methylated DNA were amplified
on the same plate with patient samples. These controls ensured the completion of bisulfite
reaction and the reliability of the results.

5.3.2. Gene-specific promoter methylation analysis

In epigenetic studies of HCC, the aberrant promoter methylation of p16, RASSF1A, ECadherin, MSH2, CCND2, SEMA3B, SPINT2, SFN, MYC, MAGEA3B, FHIT, and
MGMT was frequently reported in previous studies [19, 27-30]. We selected these genes
for methylation screening. In addition, another nine genes including p14, p15, GATA4,
NDRG4, OPCML, SEPT9, SFRP2, TFPI2, and ALX4, which were found to be highly
hypermethylated in colon cancer and related to the tumorigenesis [31-34], were also
examined in this study. For all the 40 pairs of matched cancerous and noncancerous liver
tissue samples, 4 pairs of patient samples were found to have very low amount of DNA
and they were excluded from the methylation profiling.
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Among all the patient samples, 14 pairs of HCC cancerous and non-cancerous adjacent
tissues were first randomly selected for the screening of all genes in the training phase,
and then another 22 pairs of matched liver tissue samples were used for validating the
screened genes. The reported highly methylated genes on colon cancer were found to
have negative results for all HCC samples. In addition, the methylation rates on ECadherin, MGMT, CCND2, MYC, and FHIT were very low on both cancerous and noncancerous tissues. For all other genes, the methylation rates were listed in Table 5. 3.
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Table 5.3 The methylation profiles of ten tumor suppressor genes in the screening test
Adjacent
Cancerous liver tissue
non-cancerous tissue

Gene
No. of samples Methylation
methylated
rates

No. of samples
methylated

Methylation
rates

P16

15(36)

41%

2(36)

6%

RASSF1A

32(36)

88%

10(36)

28%

SPINT2

23(36)

57%

2(36)

6%

SFN

33(36)

92%

32(36)

89%

SEMA3B

24(36)

67%

20(36)

56%

MAGEA3

22(36)

61%

24(36)

67%

MSH2

22(36)

61%

19(36)

53%

CCND2

2(14)

14%

1(14)

7%

MYC

0(14)

0%

1(14)

7%

FHIT

1(14)

7%

3(14)

21%
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Based on these results from the screening test, p16, RASSF1A, SPINT2, SFN, SEMA3B,
MAGEA3, and MSH2 showed relatively high methylation frequencies on HCC
cancerous tissues. As a result, these seven genes were further selected for the validation
analysis on the other 22 pairs of samples (Table 5. 3). For genes p16, RASSF1A, and
SPINT2, they showed significant higher methylation rates in cancerous samples over
noncancerous samples. However, we found that the methylation frequencies of SFN,
SEMA3B, MAGEA3, and MSH2 were also high in adjacent noncancerous sample and
their methylation profiles were not adequate to distinguish these two groups.

The high methylation frequencies in non-cancerous tissues on SFN, SEMA3B, MAGEA3,
and MSH2 may be related to the field cancerization of HCC, which initiates the
malignancy with the accumulation of epigenetic and genetic damages on several tumor
suppressor genes [35, 36]. To test this explanation, we examined the methylation status of
the aforementioned seven genes in the validation study from 36 pairs of HCC and their
corresponding non-cancerous tissues. Four possibilities of methylation status in paired
samples from the same patient were proposed: 1) positive methylation in both cancerous
and non-cancerous tissues as C(+)/NC(+); 2) positive methylation in cancerous tissue but
negative in non-cancerous tissue as C(+)/NC(-); 3) negative methylation in both cancerous
and non-cancerous tissues as C(-)/NC(-); 4) negative methylation in cancerous tissue but
positive in non-cancerous tissue as C(-)/NC(+). The results after the comparison of each
gene showed that most tissue pairs had accordant alterations with the methylation status
of C(+)/NC(+) at 40%, C(+)/NC(-) at 25%, and C(-)/NC(-) at 24%. The discordant methylation
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appeared in 3% tissue pairs as C(-)/NC(+) for genes p16, RASSF1A, SEMA3B, MAGEA3,
and MSH2 (Table 5.4).
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Table 5.4. Methylation status in paired cancerous and non-cancerous samples (n=36)
from the same patient

Genes

C(-)/NC(-)

C(-)/NC(+)

C(+)/NC(-)

C(+)/NC(+)

20(56%)

1(3%)

14(39%)

1(3%)

RASSF1A

3(8%)

1(3%)

23(64%)

9(25%)

SPINT2

13(4%)

0(0%)

21(58%)

2(6%)

SFN

3(8%)

0(0%)

1(3%)

32(89%)

SEMA3B

10(28%)

2(6%)

6(17%)

18(50%)

MAGEA3

11(31%)

3(8%)

1(3%)

21(58%)

MSH2

13(36%)

1(3%)

4(11%)

18(50%)

24%

3%

25%

40%

P16

Average%
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5.3.3. Quantitative methylation analysis

Although the promoter methylation on SFN, SEMA3B, MAGEA3, and MSH2 were high
in HCC patient samples, the MSP analysis cannot differentiate the non-cancerous and
cancerous tissue with the assistance of the melting curves. To obtain the quantitative
information, we further performed RT-PCR methylation analysis of these three genes on
36 pairs of matched samples. The quantitative results were expressed as methylation
percentage, which was determined by the following equation:

QM and QTotal were the reference methylated and total DNA quantity, respectively. As
shown in Figure 5.3, Standard curves were established to determine QM and QTotal.
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A.

B.

Figure 5.3, Standard curves constructed for quantifying methylated DNA
for gene SFN (A) and total DNA using primer ACTB (B)
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As summarized in Table 5.5, the quantitative results in 36 pairs of matched HCC tissues
showed higher methylation percentage on gene SFN and MSH2 for cancerous samples
comparing with the non-cancerous ones. The methylation percentage was low in both
tissues for gene SEMA3B, and it appeared to be higher in non-cancerous tissue than in
cancerous tissue for gene MAGEA3. Currently, the cut-off value cannot be set to define
the cancerous and non-cancerous tissues based on their methylation percentage.
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Table 5.5 The methylation percentage of 4 genes on 36 pairs of HCC
cancerous/non-cancerous samples

Genes

SFN
SEMA3B
MAGEA3
MSH2

HCC Cancerous
Samples

Non-Cancerous
Samples

(Average ±S.D)

(Average ±S.D)

76%±39%

37%±25%

32

14%±8%

7%±5%

18

59%±17%

94%±26%

21

57%±28%,

21%±19%

18
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5.4. Discussion

Epigenetic analysis of promoter methylation plays an important role in the process of
tumorigenesis and biomarker discovery for disease diagnosis. Recent studies have
demonstrated that HCC had a high frequency of promoter methylation of multiple genes
[18-19, 27-30]. However, many issues regarding the comprehensive methylation profile
of a large pool of tumor-associated genes and the mechanisms of epigenetic phenomena
in cancer progress remain elusive. In this study, we decided to investigate the promoter
methylation status of multiple genes including p16, RASSF1A, E-Cadherin, MSH2,
CCND2, SEMA3B, SPINT2, SFN, MYC, MAGEA3B, FHIT, MGMT, p14, p15,
GATA4, NDRG4, OPCML, SEPT9, SFRP2, TFPI2, and ALX4. These genes are
involved in different molecular pathways of carcinogenesis such cell-cycle regulatory
(p16, p14, and p15), apoptosis (RASSF1A, SEMA3B and FHIT), cell adhesion (ECadherin), and DNA repair (MGMT). Understanding their functions in the advance
tumor stages of HCC provides the ability to predict the premalignant conditions for early
diagnosis.

The current study has successfully identified altered methylation status on several genes
using the developed quantitative methylation profiling method. Sodium bisulfite reacted
with the methylated CpG site specifically, enabling the discrimination of methylated
DNA with unmethylated DNA by methylation-specific PCR. Among the 21 tested genes,
p16, RASSF1A, SPINT2, SFN, SEMA3B, MAGEA3, and MSH2 had higher frequencies
of promoter methylation in the training phase, in which 14 pairs of cancerous versus non-
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cancerous adjacent tissues were used. Although hypermethylation of E-Cadherin,
CCND2, MYC, FHIT, and MGMT in HCC was reported in previous studies for HCC
[28-30], it was not observed in the present study. Interestingly, the methylation status of
all colon cancer related genes including p14, p15, GATA4, NDRG4, OPCML, SEPT9,
SFRP2, TFPI2, and ALX4 showed negative results for all HCC samples. This may be
explained by that the molecular functions of these genes in carcinogenesis are specific to
colon cancer, rather than HCC.

Based on the results of training phase, all the genes with low methylation rates in HCC
samples were eliminated, leaving seven genes for the validation and further screening on
another 22 pairs of matched samples. The methylation status of these seven genes were
profiled and shown that high methylation frequency of both cancerous tissue and adjacent
non-cancerous tissue for the majority of sample pairs. This phenomenon suggested field
cancerization in the surgical margin. For gene SPINT2 and SFN, their methylation status
was accordant in all the sample pairs, revealing the monoclonal expansion model in the
early cancer event. The discordant methylation status of p16, RASSF1A, SEMA3B,
MAGEA3, and MSH2 may result from the polycolonal origins of HCC. These results
indicated the complicated origins in hepatocarcinogenesis, involving both monoclonal
and polyclonal expansion of preneoplastic cells.

Due to the silenced gene expression in cancerous and non-cancerous pairs for most
hypermethylated genes, the methylation frequencies were not adequate to predict the
early event of HCC. We developed the comparative quantification assay for SFN,
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SEMA3B, MAGEA3, and MSH2 to separate HCC cancerous and non-cancerous samples.
SFN and MSH2 demonstrated higher methylation percentage compared to other genes.
However, adequate cut-off value to define cancerous from non-cancerous tissues was not
available for these two genes. These results may be due to the fact that HCC sample pairs
used in the study were mainly from advanced stage, and the field cancerization caused
the accumulative epigenetic changes in the surgical margins.

In conclusion, we examined the gene-specific alterations through promoter methylation
profiling on 21 genes using bisulfite conversion and MSP. With the comparison of HCC
cancerous and non-cancerous tissues, frequent CpG island hypermethylation was found
for p16, RASSF1A, and SPINT2. In addition, we observed the consistent methylation
status in cancerous and adjacent non-cancerous tissue for other hypermethylated genes
SFN and MSH2, resulted from field cancerization of HCC. In the future, the quantitative
methylation assays will be performed on early stage of HCC samples to better assess the
ability of these genes for its early screening. The results from the present study supported
that the DNA methylation could be an important event during carcinogenesis and a
potential biomarker for HCC diagnosis.
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